GUIDELINES

EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations

A. Nast,1,7 C. Smith,2 P.I. Spuls,3 G. Avila Valle,1 Z. Bata-Csörgő,4 H. Boonen,5 E. De Jong,6 I. Garcia-Doval,1 P. Gisondi,8 D. Kaur-Knudsen,9 S. Mahil,10 T. Mäkönen,11 J.T. Maul,12 S. Mburu,13 U. Mrowietz,14 K. Reich,15 E. Remenyik,16 K.M. Ronholt,17 P.G. Sator,18 M. Schmitt-Egenolf,19 M. Sikora,20 K. Strömer,21 O. Sundnes,22 D. Trigos,13 G. Van Der Kraaij,3 N. Yawalkar,23 C. Dressler1

1Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Department of Dermatology, Venereology and Allergology, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany
2St John’s Institute of Dermatology, London, UK
3Academic Medical Centre Amsterdam, Amsterdam, Netherlands
4University of Szeged, Szeged, Hungary
5Office-Based Dermatology Practice, Geel, Belgium
6Radboud University Medical Centre Nijmegen, Nijmegen, Netherlands
7Unidad de Investigación. Fundación Piel Sana AEDV, Madrid, Spain
8University of Verona, Verona, Italy
9University Hospital Copenhagen, Copenhagen, Denmark
10Guy’s and St Thomas’ NHS Foundation Trust, London, UK
11Helsinki University Central Hospital, Helsinki, Finland
12Department of Dermatology, University Hospital of Zürich, Zürich, Switzerland
13International Federation of Psoriasis Associations (IFPA)
14Universitätsklinikum Schleswig-Holstein, Kiel, Germany
15Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
16University of Debrecen, Debrecen, Hungary
17Aarhus University Hospital, Aarhus, Denmark
18Municipal Hospital Hietzing, Vienna, Austria
19Dermatology, Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden
20Department of Dermatology, Medical University of Warsaw, Warsaw, Poland
21Office-Based Dermatology Practice, Mönchengladbach, Germany
22Oslo University Hospital, Oslo, Norway
23Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland

*Correspondence: A. Nast. E-mail: euroguiderm@debm.de

Abstract

This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clinical and comorbid situations such as treating psoriasis vulgaris patient with concomitant psoriatic arthritis, concomitant inflammatory bowel disease, a history of malignancies or a history of depression or suicidal ideation. It further holds recommendations for concomitant diabetes, viral hepatitis, disease affecting the heart or the kidneys as well as concomitant neurological disease. Advice on how to screen for tuberculosis and recommendations on how to manage patients with a positive tuberculosis test result are given. It further covers treatment for pregnant women or patients with a wish for a child in the near future. Information on vaccination, immunogenicity and systemic treatment during the COVID-19 pandemic is also provided.

Received: 12 June 2020; Accepted: 13 August 2020

The guideline was developed by all co-authors. The EuroGuiDerm Team1 coordinated the work.

DOI: 10.1111/jdv.16926
Conflicts of Interest
The guideline development group consists of 25 experts from 14 countries, seven of which declared to have personal–financial conflict of interests, which is a total of 28% of the group members (see Table 1 of the Methods & Evidence Report). The EuroGuiDerm Team does not have any personal–financial conflict of interests to disclose regarding the subject at hand.

Funding sources
The development of this EuroGuiDerm guideline was funded by the EuroGuiDerm Centre for Guideline Development. The European Dermatology Forum is responsible for fundraising and holds all raised funds in one account. The EuroGuiDerm Team is not involved in fundraising or in the decision-making regarding which guideline (GL) or consensus statement (CS) development is funded. The decisions on which GL/CS is funded are made by the EuroGuiDerm Board of Directors independently. The EDF or any other body supporting the EuroGuiDerm is never involved in the guideline development and had no say on the content or focus of the guideline.

I. Notes on use/Disclaimer
The EuroGuiDerm guideline on the systemic treatment of psoriasis vulgaris was developed in accordance with the EuroGuiDerm Methods Manual v1.3, which can be found on the website of the European Dermatology Forum (EDF), subsection EuroGuiDerm/EDF Guidelines https://www.edf.one/de/home/Guidelines/EDF-EuroGuiDerm.html.

This work is licensed under the Creative Commons Attribution-NonCommercial-4.0. For further information on copyright in case of translation, adaptation, commercial use, etc., see EDF website. Copyright © European Dermatology Forum.

VIII Methods Section
(section identical to part 1 of the guideline)

Wording of recommendations

| Strength                      | Wording                        | Symbols | Implications                                                                                                                                 |
|-------------------------------|--------------------------------|---------|----------------------------------------------------------------------------------------------------------------------------------------------|
| Strong recommendation for the use of an intervention | 'We recommend . . .' | ▲▼ ▲▼ | We believe that all or almost all informed people would make that choice. Clinicians will have to spend less time on the process of decision-making, and may devote that time to overcome barriers to implementation and adherence. In most clinical situations, the recommendation may be adopted as a policy. |
| Weak recommendation for the use of an intervention | 'We suggest . . .' | ▲▼ ▲▼ | We believe that most informed people would make that choice, but a substantial number would not. Clinicians and health care providers will need to devote more time on the process of shared decision-making. Policy makers will have to involve many stakeholders and policy making requires substantial debate. |
| No recommendation with respect to an intervention | 'We cannot make a recommendation with respect to . . .’ | ▲▼ ▲▼ | At the moment, a recommendation in favour or against an intervention cannot be made due to certain reasons (e.g. no reliable evidence data available, conflicting outcomes, etc.) |
| Weak recommendation against the use of an intervention | 'We suggest against . . .' | ▲▼ ▲▼ | We believe that most informed people would make a choice against that intervention, but a substantial number would not. |
| Strong recommendation against the use of an intervention | 'We recommend against . . .' | ▲▼ ▲▼ | We believe that all or almost all informed people would make a choice against that intervention. This recommendation can be adopted as a policy in most clinical situations. |
The recommendations are presented throughout this guideline as displayed below: first the content, then the arrows and colours indicating the direction and the strength of the recommendations, respectively, and lastly the rate of expert agreement (consensus strength). Evidence-based recommendations are indicated as such.

We **recommend** to do tuberculosis screening according to local regulations. 

| Specific circumstances | Conventional systemic agents | Therapy |
|------------------------|-------------------------------|---------|
| Concomitant psoriatic arthritis | | |
| Chronic inflammatory bowel disease: Crohn’s Disease | | |
| Chronic inflammatory bowel disease: Ulcerative colitis | | |
| Diabetes mel./metabolic syndrome | | |
| Dystipidaemia | | |
| Advanced heart failure | | |
| Heart Disease: Ischemic heart disease | | |
| Concomitant latent / treated TB | | |
| Pregnancy | | |

**IX. Main Recommendations**
The EuroGuiDerm guideline development group considers the time a treatment has been available a relevant factor when considering different treatment options (Tables 1 and 2).

### 3 Guidance for specific clinical and comorbid situations

#### 3.1. Psoriatic arthritis: How should psoriasis patients with concomitant psoriatic arthritis be managed?

This chapter is based on the related chapter in previous versions of this guideline. An existing systematic review and meta-analysis were updated, details of which can be found in the Methods and Evidence report.

---

**Table 1: Overview of ‘conventional’ treatment options and the expert assessment of their suitability in specific treatment circumstances (decision grid I)**

| Specific circumstances | Conventional systemic agents | Therapy |
|------------------------|-------------------------------|---------|
| Concomitant psoriatic arthritis | | |
| Chronic inflammatory bowel disease: Crohn’s Disease | | |
| Chronic inflammatory bowel disease: Ulcerative colitis | | |
| Diabetes mel./metabolic syndrome | | |
| Dystipidaemia | | |
| Advanced heart failure | | |
| Heart Disease: Ischemic heart disease | | |
| Concomitant latent / treated TB | | |
| Pregnancy | | |

**Symbols**

- **Strong consensus**
  - We believe that all or almost all informed people would make that choice.
- **100% agreement**
  - We believe that most informed people would make that choice, but a substantial number would not. See background text and specific recommendations
- **Preferred conventional**
  - We believe that most informed people would make a choice against that intervention, but a substantial number would not.

---

*Adapted from GRADE*
Treatments are usually categorized as NSAIDs (e.g. diclofenac), conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), e.g. MTX, targeted synthetic (ts)DMARDs (e.g. apremilast) and biological (b)DMARDs (e.g. TNF antagonists).

Head-to-head trials allowing direct comparison between the different groups or between the individual drugs are extremely rare. Indirect comparisons, e.g. network meta-analyses, are limited by the low number of trials for psoriatic arthritis. See Table 3 for an overview of RCT data on psoriatic arthritis.
Non-steroidal anti-inflammatory drugs (NSAIDs). The role of NSAIDs is usually in the relief of symptoms of psoriatic arthritis for patients with mild and non-erosive articular as well as para-articular involvement. Treatment of NSAIDs should be limited to the lowest required dosage for the shortest period as needed.14

Conventional synthetic DMARDs (e.g. MTX).

MTX is recommended, taking the label, the efficacy on skin and peripheral joints, the safety profile and the available long-term experience in the treatment of rheumatic joint disorders into account.14

Table 3  Summary of the results for drugs approved for psoriasis of the skin and psoriatic arthritis (Dressler et al.13 updated, see methods report)

| Patients achieving ACR20 | Patients with at least one adverse event |
|-------------------------|------------------------------------------|
| RR  95% CI                | Quality of the Evidence (GRADE)           |
| RR  95% CI                | Quality of the Evidence (GRADE)           |

**Head-to-head comparisons**

| ETA 50mg + MTX vs. MTX 20mg QW | 1.28  1.11 to 1.48 | LOW 1.01  0.92 to 1.11 | MODERATE |
| INF 5mg/kg W 0, 2, 6, 14 + MTX vs. MTX 15mg QW | 1.40  1.07 to 1.84 | VERY LOW 1.65  1.08 to 2.52 | VERY LOW |
| IXE 80mg Q2W vs. ADA 40mg Q2W | 1.08  0.86 to 1.36 | LOW 1.02  0.83 to 1.25 | MODERATE |
| IXE 80mg Q4W vs. ADA 40mg Q2W | 0.96  0.86 to 1.06 | LOW 1.14  1.01 to 1.28 | VERY LOW |

**Placebo comparisons**

| ADA 40mg EOW vs. PBO | 3.35  2.24 to 4.99 | MODERATE 0.67  0.50 to 0.89 | VERY LOW |
| APR 30mg BiD vs. PBO | 1.94  1.59 to 2.38 | MODERATE 1.24  1.12 to 1.36 | LOW |
| APR 20mg BiD vs PBO | 1.86  1.49 to 2.31 | MODERATE 1.27  1.15 to 1.41 | LOW |
| CZP 400mg Q4W vs. PBO | 2.38  1.68 to 3.31 | MODERATE 1.05  0.90 to 1.23 | MODERATE |
| CZP 200mg Q2W vs. PBO | 2.71  1.95 to 3.76 | MODERATE 1.01  0.86 to 1.19 | MODERATE |
| ETA 25mg BiW vs. PBO | 4.05  2.56 to 6.40 | n.d. |
| INF 5mg/kg W 0, 2, 6, 14 vs. PBO | 4.38  2.24 to 8.56 | MODERATE 1.13  0.87 to 1.47 | LOW |
| IXE 80mg Q2W vs. PBO | 2.21  1.71 to 2.86 | MODERATE 1.39  1.09 to 1.78 | LOW |
| IXE 80mg Q4W vs. PBO | 2.25  1.59 to 3.18 | MODERATE 1.41  1.10 to 1.79 | LOW |
| MTX 7.5mg QW vs. PBO | 1.82  0.97 to 3.40 | LOW n.d. |
| SEC 150mg Q4W vs. PBO | 2.44  2.10 to 2.84 | HIGH 1.03  0.95 to 1.12 | HIGH |
| SEC 150mg Q4W + LD vs. PBO | 2.06  1.70 to 2.49 | HIGH 1.01  0.89 to 1.15 | MODERATE |
| SEC 300mg Q4W + LD vs. PBO | 2.28  1.87 to 2.80 | MODERATE 1.02  0.89 to 1.16 | MODERATE |
| UST 45mg W 0, 4 and Q12W vs PBO | 1.95  1.52 to 2.50 | HIGH n.d. |
| UST 90mg W 0, 4 and Q12W* vs PBO | 2.26  1.80 to 2.82 | MODERATE 0.96  0.75 to 1.24 | VERY LOW |

Abbreviations: 95% CI, 95% confidence interval; ACR20, 20% improvement in American College of Rheumatology response criteria; ADA, adalimumab; APR, apremilast; BiD, twice a day; BiW, twice a week; CZP, certolizumab pegol; EOW, every other week; ETA, etanercept; INF, infliximab; kg, kilograms; IXE, ixekizumab; LD, loading dose; mg, milligrams; MTX, methotrexate; PBO, placebo; Q12W, every 12 weeks; Q2W, once every 2 weeks; Q4W, once every 4 weeks; QW, once a week; RR, risk ratio; Sec, secukinumab; UST, ustekinumab; W, week.

*One study (Gottlieb et al. 2009) reported induction dose of QW (weeks 0–3).

We recommend starting a conventional synthetic DMARD (MTX) early to prevent progression of disease and erosive destruction of joints for patients with moderate to severe psoriasis and peripheral active joint involvement (PsA) despite the usage of NSAIDs, or glucocorticoid site injections if applicable and/or potential poor prognosis due to polyarthritis, increased inflammatory markers and erosive changes, and extra-articular musculoskeletal manifestations.

We do not recommend synthetic monotherapy DMARDs (MTX) for the treatment of axial involvement or enthesitis, as they appear to be not effective in these patients.
Biological DMARDs.
Previously, guidelines have given a preference to TNF alpha antagonists over other bDMARDs. In the guideline group’s view, a preference for inhibitors of TNF treatments for PsA is no longer mandatory, since ustekinumab and the IL-17A antibody treatments might be equally effective; however, more data are needed for its real-life long-term efficacy, safety and comedication.

The treatment with a biological DMARD can be performed in monotherapy or in combination with a conventional synthetic DMARD.

Other treatment options. As apremilast is less efficacious than bDMARDs, it is suggested for patients with concomitant psoriatic arthritis and an inadequate response to at least one csDMARD, in whom biological treatments are not appropriate.

Local injection of glucocorticoids can be recommended in patients with active mono- or oligoarthritis, dactylitis and in enthesial areas (enthesitis).

Systemic usage of glucocorticoids should not be standard for treatment of psoriatic arthritis, but if needed, e.g. during flares, ‘systemic steroids at the lowest effective dose may be used with caution’15. Tapering of glucocorticoids should be done slowly and stepwise when feasible.

3.2 Inflammatory bowel disease: How should psoriasis patients be managed with concomitant inflammatory bowel disease?
Narrative review of the existing literature and an assessment of approval status of psoriasis therapies for Crohn’s disease and ulcerative colitis were conducted. Existing guidelines were consulted.16–18

Results/Answer
Likely due to an overlap in the pathophysiology and genetic background of psoriasis and Crohn’s disease, the risk of psoriasis...
patients developing Crohn’s disease is approximately two- to threefold higher compared to the general population.19,20

The IL-17A antibody secukinumab and the IL-17RA antibody brodalumab have failed in studies in Crohn’s disease, with some patients experiencing worsening of their disease during treatment.21,22 Cases of newly onset Crohn’s disease and ulcerative colitis have been observed during treatment of psoriasis patients with IL-17 inhibitors. The observed signal is, however, low, and it is presently unclear if the rate exceeds the rate expected in a psoriasis population.23 In a recent summary of the safety observed in clinical trials of secukinumab in psoriasis, for example, the event rate per 100 patient-years of exposure was 0.05 (95% confidence interval 0.02–0.1) for Crohn’s disease (approximately one case per 2000 patients treated for one year) and 0.1 (0.07–0.2) for ulcerative colitis (approximately one case per 1000 patients treated for one year).24 Since anti-TNF antibodies and ustekinumab, and possibly anti-IL-23 antibodies, are effective in treating Crohn’s disease,25 the use of these biologics in psoriasis may decrease the occurrence of new-onset Crohn’s disease cases in psoriasis patients.26

The prescription information for secukinumab and ixekizumab include a warning regarding the use of these drugs in patients with inflammatory bowel disease, while active Crohn’s disease is a contraindication for the use of brodalumab.

In contrast, ustekinumab, adalimumab, infliximab and certolizumab are all targeted therapies approved not only for the treatment of psoriasis, but also for the treatment of Crohn’s disease and, in the case of adalimumab, infliximab and ustekinumab, ulcerative colitis. Notably, the anti-TNF fusion protein etanercept failed in clinical trials in Crohn’s disease (reviewed in Whitlock SM et al. 201827).

There is an ongoing phase II/III clinical development programme for the IL-23p19 inhibitors guselkumab and risankizumab in Crohn’s disease and ulcerative colitis. In the case of risankizumab, positive clinical effects have been published for the induction and long-term treatment of patients with Crohn’s disease25,28 and are supported by immunological findings in the intestinal mucosa of patients with Crohn’s disease receiving the drug.29 There are several published case reports on the successful use of guselkumab in patients with Crohn’s disease.30,31

Due to their intestinal side-effect profile with a relatively frequent induction of abdominal pain, loose stools and diarrhoea, fumarates should not be used in patients with inflammatory bowel disease. Severe gastrointestinal diseases are listed as contraindication in the prescription information of Fumaderm® and Skilarence®.32

Inhibition of PDE4 with apremilast has shown positive effects in a phase 2 trial with ulcerative colitis.32 Methotrexate has limited efficacy in Crohn’s disease33,34 and probably even less in ulcerative colitis,35,36 but there is a considerable body of experience and no signal for a worsening of these conditions.

Acitretin may be considered neutral in patients with psoriasis and inflammatory bowel disease and has been used in the treatment of patients with inflammatory bowel disease that developed psoriasisform lesions (including cases of so-called paradoxical psoriasis) during treatment with TNF antagonist.37 Ciclosporin is frequently used in the treatment of steroid-refractory ulcerative colitis and has demonstrated long-term outcomes similar to those of infliximab.38

3.3 Cancer: How should psoriasis patients with a history of malignancies be managed?

This chapter is based on the related chapter in previous versions of this guideline.7,8 A systematic search was conducted, details of which can be found in the Methods & Evidence Report.

Results/Answer Theoretically, immunomodulatory therapies used for psoriasis have the potential to affect the course of a malignant disease, and the safety of using them in this context is uncertain.

In clinical practice, different scenarios are associated with different risks and the answer might not be the same for each of them. Patients can present with precancer (such as cervical dysplasia, colonic polyps or Barrett’s oesophagus), low risk cancer (NMSC, cancer with a long period of non-recurrence, usually defined as more than 5 years) or high-risk cancer (active cancer, recent aggressive cancer).

Available evidence to guide clinicians in these situations is scarce. Patients with malignancies are excluded from randomized clinical trials, so RCTs will not provide valid answers. Information about patients with previous cancer can only come from observational studies, which are less valid, as they are commonly affected by confounding by indication. There are techniques that can help control for this type of confounding, but these kinds of analyses require large numbers of patients that are difficult to enrol. This power issue is the reason for results usually being given for different cancers merged and also for different drugs grouped.

Most of the data available is of marginal relevance to this question:

Overall risk of cancer in psoriasis Psoriasis is associated with increased mortality due to many diseases, including an increased risk of cancer. It is not clear whether this is due to the disease itself, or is influenced by lifestyle factors (mainly alcohol and smoking) or therapy.39

A recent systematic review and meta-analysis of 112 observational cohort studies of patients with psoriasis and psoriatic arthritis revealed a slightly increased risk of several cancer types, particularly keratinocyte cancer and lymphoma.40

Association of therapy and incident cancer in psoriasis and other immune-mediated disease Some studies have studied the possible association of the use of systemic therapies for...
psoriasis and incident of cancer (in patients without previous history of cancer).

A systematic review of RCTs and observational studies exploring the risk of cancer in psoriasis patients treated with biologics described increased risk of non-melanoma skin cancer in those patients being treated with anti-TNFs. However, included studies lacked adjustment for highly relevant confounding factors such as prior phototherapy. Data on other cancers do not show a risk associated with exposure to drugs. However, the studies are likely to be underpowered to ascertain the risk of individual types of cancer.\(^4^4\) Vaengebjerg et al did not find increased risk of cancer in patients with psoriasis and psoriatic arthritis on biologics compared with other systemic therapies.\(^4^0\)

There are also some studies describing the risk of cancer associated with systemic therapy for other immune-mediated disorders, mainly rheumatoid arthritis, other rheumatic disorders and inflammatory bowel disease. Results in these disorders might not be appropriately extrapolated to psoriasis patients, as psoriatic patients receive less immunosuppressive therapy (especially corticosteroids) and the associated disorders are different.\(^4^2\)

Most studies are reassuring and did not find a relationship between exposure to anti-TNFs and risk of incident cancer in rheumatoid arthritis and psoriatic arthritis.\(^4^3\) Luo et al, analysing data from nine cohorts, described an increased risk of cancer in psoriatic arthritis patients treated with disease-modifying antirheumatic drugs, which was not seen in patients receiving biologics. However, this increase was due to NMSC and included studies have not considered the likely effect of previous PUVA therapy.\(^4^4\) SmPCs of TNF inhibitors contain information regarding the risk of lymphoma/leukaemia. However, these are rare events and data supporting this association are conflicting. So far no such association have been shown for psoriasis patients.\(^3^1\)

### Risk of cancer recurrence in patients exposed to systemic therapy for psoriasis

Few studies provide information that is relevant for answering this question.

Regarding patients with precancerous conditions (data available only for cervical dysplasia), a study using routine data of women with rheumatoid arthritis (RA) describes that initiation of therapy with a biological disease-modifying antirheumatic drug (bDMARD) was associated with an increased, but not statistically significant, risk of high-grade cervical dysplasia or cervical cancer compared to initiation of a nonbiological (nb)DMARD.\(^4^5\) Conversely, a review analysing 238 women with RA and a history of cervical carcinoma in situ, no genital cancer was observed in the TNFi-treated group over a median of 5.2 years of follow-up compared with two incidents of genital cancer in the bDMARD-treated group, during a median follow-up of 3.9 years.\(^6^6\)

A systematic review of patients with a history of cancer and exposed to anti-TNF therapy assessing for the risk of the occurrence of new cancer or cancer re-occurrence compared to nonbiologic disease-modifying antirheumatic drugs (DMARD), included nine studies with 11 679 patients. None of them were studies on psoriasis. The outcome measures were heterogeneous, with many studies focused on describing NMSC. Overall, the study did not find an increased risk of recurrence in patients treated with anti-TNFs compared to nbDMARD.\(^4^7\)

A retrospective study, based on routine data, of patients with rheumatoid arthritis and inflammatory bowel disease, and a previous NMSC, described an increased risk of a second NMSC in

| Recommendation | Description | Level |
|----------------|-------------|-------|
| **We recommend** | taking the burden of psoriasis, and the risk of cancer worsening or recurrence (pre-cancer vs low risk vs high risk) into account for shared therapeutic decision making. | ↑↑ |
| For patients with recent malignancy we **recommend** | topical therapies, phototherapy (narrow band UVB) * and/or **acitretin**. | ↑↑ |
| *except patients with a recent, and/or high risk of cutaneous malignancy* | | |
| **We recommend** | to discuss the decision to initiate immunosuppressive therapies, in psoriasis patients with a current or recent diagnosis of cancer in the previous five years case-by-case with cancer specialists and to reach an informed decision, respecting the patient’s preference. | ↑↑ |
| In case of inadequate response to topical therapies, phototherapy, (narrow band UVB) and/or **acitretin** we **suggest** | using MTX in psoriasis patients with a previous history of cancer. * | ↑ |
| (*for patients with history of non melanoma skin cancer, see background text)* | | |
| **We suggest** | **apremilast** can be used in psoriasis patients with a previous history of cancer despite the lack of long term experience based on pathophysiological considerations on a case-by-case basis including discussions with cancer specialists. | ↑ |
| **We suggest** | using ciclosporin in psoriasis patients with a previous history of cancer. | ↓ |
| **We suggest** | **anti-TNF**, ustekinumab can be used based on existing safety data on a case-by-case basis including discussion with cancer specialist. | ↑ |
| **We suggest** | **anti-IL17**, anti IL23, can be used in psoriasis patients with a previous history of cancer despite the lack of long term experience based on pathophysiological considerations on a case-by-case basis including discussion with a cancer specialist. | ↑ |

| Strong consensus | 100% agreement | EXPERT CONSENSUS |
|------------------|----------------|-----------------|
| ↑↑ | | Strong consensus |
| 100% agreement | | EXPERT CONSENSUS |

\(^1\)Due to personal-financial conflict of interest 3 abstentions
patients treated with methotrexate that was higher with longer exposures. Anti-TNF use was also associated with an increased risk, mostly in a subgroup (patients with RA and concomitant use of methotrexate).\textsuperscript{48}

Another systematic review analysed the risk of cancer recurrence in patients with immune-mediated diseases exposed to immune-suppressive therapies. They included 16 observational studies with 11,702 participants after a cancer diagnosis and with 1698 new or recurrent cases of cancer. Only one very small study, and not contributing to the final analysis, was focused on psoriasis patients. Overall, rates of cancer recurrence were similar among participants receiving anti-TNF therapy, immune modulator therapy or no immunosuppression, but were higher among patients receiving combination immune suppression.\textsuperscript{49}

French guidelines have reviewed the risk of cancer associated with systemic therapies. Ciclosporine has been clearly linked to an increased risk of cancer and a recommendation to avoid it has been issued. Evidence from larger patient cohort over long periods of time on the risk of the newer drugs such as the anti-IL-17, anti-23 antibodies and apremilast is still very scarce.\textsuperscript{17} From a theoretical point of view, acitretin has lower efficacy but might also have the lowest risk in these patients. Phototherapy is associated with skin cancer, but not with other cancers. Although evidence is not strong, there does not seem to be a difference in risk with methotrexate and anti-TNFs, except for a possible increase in risk of NMSC for methotrexate.\textsuperscript{17}

### 3.4 Depression: How should psoriasis patients with a history of depression and/or suicidal ideation be managed?

This chapter is based on the related chapter in previous versions of this guideline.\textsuperscript{7,8} A systematic search was conducted, details of which can be found in the Methods & Evidence report.

**Results/Recommendations** Psoriasis is associated with a higher risk for psychiatric comorbidity including anxiety and depression while results on suicide ideation and suicide are more unclear.\textsuperscript{1,8,50–53} In general, interventions that are effective for psoriasis correspondingly also improve symptoms of depression. Clinical studies using adalimumab, etanercept, ustekinumab, ixekizumab, guselkumab or fumarates for the treatment of psoriasis have shown that all these anti-inflammatory drugs not only improve psoriatic manifestations, but also symptoms of depression.\textsuperscript{52,54–59} In a head-to-head study, guselkumab was associated with greater improvements in symptoms of depression compared with adalimumab.\textsuperscript{56} In a prospective, longitudinal registry study, biologic therapy was found to have the greatest improvement in symptoms of depression followed by conventional systemic therapy and phototherapy.\textsuperscript{18,60} Taken together, these data suggest that the more effective the intervention for psoriasis, the greater the benefit to the mood. However, whether the overall beneficial effect on depressive symptoms is direct, or indirect (through improvement in psoriasis and therefore mood) is not clear.

Systemic treatments for psoriasis with special attention to a possible increased risk of depression, suicide ideation and completed suicide are discussed below:

**Acitretin:** Acitretin has been reported to be associated with depression in some case reports.\textsuperscript{61,62} However, more recent reviews of the literature conclude that except for very few cases of depression and suicidal ideation there are no convincing evidence-based data to support an association between acitretin and depression/suicidality.\textsuperscript{63,64} A formal review of retinoids (including acitretin and isotretinoin) carried out by EMA’s Pharmacovigilance Risk Assessment Committee in 2018\textsuperscript{65} concluded that it was not possible to identify a clear increase in the risk of neuropsychiatric disorders in people taking oral retinoids compared to those that did not. However, the EMA decided to include a warning about the possible risk in the product information for oral retinoids, since PRAC noticed that severe skin disorders themselves increase the risk of psychiatric disorders.\textsuperscript{66} Based on the above, the guideline group did not consider there to be sufficient evidence to specifically counsel against use of acitretin in those patients with mood disorders but, in common with all systemic therapies, clinicians should monitor for mood changes given that people with psoriasis are at increased risk of anxiety and depression.

**Brodalumab:** In two out of three phase III studies of efficacy and safety of brodalumab in patients with plaque psoriasis (AMAGINE 1-3), cases of suicide were reported (two patients in each of studies 1 and 2).\textsuperscript{67,68} An expert opinion (2019) discussing these observed cases of suicide highlighted the following aspects\textsuperscript{69}: Further review of the suicides by the Columbia Classification Algorithm of Suicide Assessment Review Board confirmed only three of the cases as suicides. All of them had underlying psychiatric disorders or stressors and all three suicides occurred at one centre. Both symptoms of depression and anxiety decreased during treatment with brodalumab.\textsuperscript{68}

In the European SmPC, the reported suicidal ideation and behaviour, including completed suicide in patients treated with brodalumab, was mentioned. However, it was also stated that a causal association between treatment with brodalumab and increased risk of suicidal ideation and behaviour has not been established. In the SmPC, it is recommended that risk and benefit of treatment with brodalumab should be carefully weighed for patients with a history of depression and/or suicidal ideation. Patients, caregivers and families should be advised of the need to be alert for the emergence or worsening of depression, suicidal ideation, anxiety or other mood changes, and they should contact their healthcare provider if such events occur. If a patient suffers from new or worsening symptoms of depression and/or suicidal ideation or behaviour.
is identified, it was recommended to discontinue treatment with brodalumab.70

Apremilast: Results from two phase III studies including patients with moderate-to-severe psoriasis (ESTEEM 1 and ESTEEM 2) with open-label extension for up to four years showed that patient-reported depression occurred in 1.4% of patients treated with apremilast and in 0.5% of receiving placebo. The incidence of depression did not increase over time. There was one suicide attempt, and no completed suicides with apremilast.71 Similar results were achieved in an open-label extension study (for up to additional four years) of three phase III studies of patients with psoriatic arthritis (PsA); 1.2% in patients treated with apremilast and 0.8% in patients receiving placebo. There were two suicide attempts, and no completed suicides with apremilast.72 Postmarketing experience, including five cases of completed suicides, was reported and a new safety information was published for apremilast provided by Celgene in agreement with the European Medicines Agency and the Health Products Regulatory Authority in 2016.73 In here, it was stated that evidence from clinical trials and postmarketing experience suggested a causal association between suicidal ideation and behaviour with the use of apremilast. The SmPC and patient leaflet for apremilast were updated to add a warning about depression (common adverse reaction (≥1/100 to <1/10)) and suicidal behaviour and ideation (uncommon adverse reaction (≥1/1000 to <1/100)).74

It was recommended that risks and benefits of starting or continuing treatment with apremilast should be carefully assessed in patients with previous or existing psychiatric symptoms or if concomitant treatment with other medicinal products likely to cause psychiatric events are in use or intended. Additionally, it was recommended to discontinue treatment with apremilast in patients suffering from new or worsening psychiatric symptoms, or if suicidal ideation or suicidal attempt is identified.

Moderate-to-severe psoriasis is commonly accompanying with metabolic disorders including type 2 diabetes mellitus, obesity, dyslipidaemia, nonalcoholic fatty liver disease and metabolic syndrome.75 In particular, several meta-analyses confirmed the association between psoriasis and diabetes as well as the new AAD guidelines18,75-77 Amstrong et al.75 found that psoriasis had an odds ratio (OR) of 1.59 (95% CI, 1.38–1.83) for diabetes. The pooled OR was 1.53 (95% CI, 1.16–2.04) for mild psoriasis and 1.97 (95% CI, 1.48–2.62) for severe psoriasis. A nationwide population-based cohort study involving 14 158 adults with psoriasis confirmed that the risk of diabetes in psoriatic patients is correlated to the severity of psoriasis.78 The association between psoriasis and diabetes could be explained considering a common genetic background, insulin resistance and the unhealthy lifestyles such as overeating and sedentary life, which are common in patients with psoriasis.79

In addition, there is a strong association between psoriasis and obesity which induces itself insulin resistance.80 Obesity itself is a significant risk factor to develop type 2 diabetes.81 Systemic treatments for psoriasis could also impair glucose homeostasis and/or other metabolic parameters, especially in case of continuous and prolonged use. Short-term treatment with methotrexate does not appear to have a negative effect on carbohydrate metabolism parameters in patients with psoriasis or psoriatic arthritis.81-83 However, MTX should be administered with caution in the case of diabetes and obesity, due to the increased risk of hepatic fibrosis when the cumulative dose exceeds 1.5 g.84,85 Ciclosporin can increase insulin resistance, interfere with fatty acid metabolism favouring the development of dyslipidaemia and the increase of serum uric acid.86 In a prospective cohort study on the Psocare registry, it was found that CsA was associated with a significant risk of developing diabetes at week 52, which is not surprising because the calcineurin inhibitors either tacrolimus and CsA are associated with a higher risk of new-onset diabetes in transplant recipients.87

3.5 Diabetes: How should psoriasis patients with diabetes mellitus be managed?

A systematic review was conducted, see Methods & Evidence Report.

Results/Answer Although no treatment is fully contraindicated in case of diabetes, ciclosporin is better avoided because it could favour insulin resistance, particularly on long-term treatment course.

We recommend to be aware of signs and symptoms of anxiety and depression in patients with psoriasis and monitor for symptoms of depression and/or suicidal ideation or anxiety during systemic treatments for psoriasis especially in those with a history of any of the above.

We suggest using alternatives to brodalumab and apremilast in patients with a history of depression and/or suicidal ideation.

© 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.
common issue in clinical practice. A bodyweight gain could occur in patients treated with TNF-α antagonists. In contrast, ustekinumab and IL-17 inhibitors usually do not increase bodyweight in patients with chronic plaque psoriasis. Apremilast has been shown to cause weight loss in clinical trials. Studies addressing the effects of TNF-α blockade on glucose homeostasis in patients with psoriasis and/or PsA were very limited and gave conflicting results. The Homeostasis Model Assessment (HOMA) and the Quantitative Insulin Sensitivity Check Index (QUICKI) are two widely used non-invasive surrogate markers of insulin resistance, used in the following studies. A study in 62 patients with chronic inflammatory rheumatic diseases, of whom 18 patients were affected by PsA, did not show any significant improvement in glucose homeostasis during the first six months of treatment with TNF-α inhibitors. A recent prospective study in a cohort of 210 PsA patients treated with various anti-TNF-α inhibitors (adalimumab n = 70, etanercept n = 70) or MTX (n = 70) found that those receiving TNF-α inhibitors had significant improvements in glucose levels and other features of the metabolic syndrome compared with those treated with MTX. Similarly, the effects of TNF-α inhibitors on insulin sensitivity/resistance in patients with psoriasis gave discordant results. A small randomized, double-blind study in twelve psoriatic patients at high risk of developing type 2 diabetes failed to observe a significant effect of a two-week treatment with etanercept on insulin secretion and sensitivity. No significant changes in either insulin sensitivity or levels of fasting blood glucose were observed in a study in psoriatic patients after twelve weeks of treatment with adalimumab. In contrast, in two different studies, respectively, on nine and 89 patients with plaque psoriasis etanercept improved insulin sensitivity. Other TNF-α inhibitors also appear to improve insulin sensitivity in diabetic and non-diabetic patients with psoriasis.

A pooled analysis of data from the phase III randomized controlled trials for secukinumab showed a neutral effect on fasting plasma glucose, lipid parameters and liver enzymes. In patients with fasting plasma glucose > 125 mg/dL at baseline (diagnostic criterion for diabetes) secukinumab treatment presented a trend towards lowering fasting glucose concentration compared to placebo treatment during the first 12 weeks. Finally, patients with moderate-to-severe psoriasis are candidate for interventions aimed to reduce the cardiovascular risk. Screening for cardiovascular risks including diabetes, hypertension and dyslipidaemia should be recommended for all psoriasis patients. Non-pharmacological interventions, such as bodyweight loss, should be recommended to obese patients. Indeed, it has been reported that low calorie diet inducing a moderate weight loss (i.e. 5 to 10% of bodyweight) increases the responsiveness of obese patients with moderate-to-severe chronic plaque psoriasis to systemic treatments. Moreover, bodyweight loss could also increase insulin sensitivity in obese patients with psoriasis.

Psoriasis patients who suffered also from diabetes showed a lower response rate to secukinumab (n = 867) as well as to ustekinumab (n = 318) analysed in pooled phase III data from the FIXTURE, ERASURE and CLEAR study. Pinter et al. suggested an up dosing to optimize the treatment outcome to 300 mg secukinumab every two weeks instead which is tested in patients >90 kg. The inflammatory history in cardiometabolic comorbidities including diabetes might rather influence the therapy response then the severity of psoriasis itself, which can be interpreted as an expression of the higher inflammatory burden. However, further studies are needed to understand the mechanisms why cardiometabolic comorbidities are associated with lower response rates.

Etanercept does not have an impact on the glycaemic control in diabetes patients which was shown in the PRISTINE trial.

Finally, it should be considered that diabetic nephropathy eventually occurring in patients with psoriasis could reduce the clearance of any systemic treatments for psoriasis including MTX and CsA. CsA should be considered cautiously in patients with diabetes mellitus as significantly increased serum creatinine concentration could be observed.

In addition to any medical treatment, appropriate supportive care should be offered, e.g. weight loss programmes for obese patients with metabolic syndrome or dyslipidaemia.

---

| **We suggest against** | using ciclosporin or MTX as a first line treatment in patients with diabetes and/or features of the metabolic syndrome. |
|------------------------|-----------------------------------------------------------------------------------------------------|
| **Consensus**<sup>1</sup> | 89% agreement |
| **EXPERT CONSENSUS**   | 89% agreement |

| **We suggest against** | using acitretin as a first line treatment in patients with dyslipidaemia. |
|------------------------|--------------------------------------------------------------------------|
| **Strong consensus**<sup>1</sup> | 100% agreement |
| **EXPERT CONSENSUS**   | 100% agreement |

<sup>1</sup>Due to personal-financial conflict of interest 2 abstentions

---

### 3.6. Heart disease: How should psoriasis patients with ischaemic heart disease and/or congestive heart failure be managed?

This chapter is based on the related chapter in previous versions of this guideline. A systematic search was conducted, details of which can be found in the Methods & Evidence Report.
Results/Recommendations

Ischaemic heart disease/atherosclerosis

Summary/key points

- Patients with psoriasis have an approximately two- to threefold increased relative risk to develop cardiovascular events such as myocardial infarction or stroke compared to individuals without psoriasis. The cardiovascular risk seems to correlate with disease severity. The link between psoriasis and cardiovascular disease is likely to be driven by an increased prevalence of classical cardiovascular risk factors among patients with psoriasis such as the components of the metabolic syndrome. There is also evidence for an independent risk conferred by the systemic inflammatory nature of the disease.
- A careful history should be obtained from all patients to determine whether they have established cardiovascular disease. Appropriate investigations and treatment should be initiated in accordance with current European Society of Cardiology guidance.112
- Patients without a history of cardiovascular disease should have their cardiovascular risk factors assessed and be given lifestyle advice including the avoidance of smoking, a healthy diet, increased physical activity and a healthy blood pressure with other treatment in accordance with current European Society of Cardiology guidance.113,114

| We suggest against | cyclosporine or acitretin as preferred treatments in patients with psoriasis and ischemic heart disease. |
|--------------------|-------------------------------------------------------------------------------------------------------------|
|                    | Strong consensus1                                                                                                |

| We suggest         | methotrexate as preferred first-line therapy in patients with psoriasis and ischemic heart disease* if other patient characteristics do not preclude its use. |
|--------------------|----------------------------------------------------------------------------------------------------------------|
|                    | 100% agreement                                                                                               |

| We suggest         | anti-TNFs, ustekinumab, and IL-17 inhibitors as preferred targeted therapies in patients with psoriasis and ischemic heart disease*. |
|--------------------|----------------------------------------------------------------------------------------------------------------|
|                    | EXPERT CONSENSUS                                                                                             |

*Due to personal-financial conflict of interest 3 abstentions *In case of concurrent metabolic heart failure, also note the recommendations from the respective section

With the exception of methotrexate, there are no studies formally evaluating the effect of any antipsoriatic therapy as a treatment for coronary heart disease. In general, it seems that the reduction of psoriatic inflammation is beneficial in psoriatic patients with cardiovascular comorbidity (indirect effect), but direct effects of treatments for psoriasis on atherosclerotic inflammation may also play a role.

- Multiple studies with different therapies have produced evidence on parameters of cardiovascular risk and/or assessed cardiovascular events during the treatment of patients with psoriasis.
- From these studies, it appears that methotrexate, the anti-TNFs, in particular adalimumab, and ustekinumab improve parameters of cardiovascular risk in patients with psoriasis.
- While in some experimental models IL-17 has been associated with stabilizing properties of unstable atherosclerotic disease, treatment with IL-17 inhibitors has not been associated with an increased rate of cardiovascular events. Moreover, inhibition of IL-17, especially with secukinumab, has shown to improve surrogate markers of endothelial dysfunction.

- The data available on inhibitors of IL-23p19 indicate that they are safe in patients with cardiovascular comorbidity, but information on their potential effects on cardiovascular factors risk is limited.
- Treatment with apremilast is associated with weight loss in some patients. Experimental studies indicate potentially beneficial effects of apremilast in models of atherosclerosis. Neither clinical trial data nor observational studies indicate that apremilast is associated with an increased risk of cardiovascular events in psoriasis patients with ischaemic heart disease or cardiovascular risk factors.
- There is no evidence that fumarates are associated with increased cardiovascular events in patients with ischaemic heart disease.
- Ciclosporine may induce or worsen arterial hypertension, a condition often found in patients with ischaemic heart disease, and worsen dyslipidaemia. The metabolism of ciclosporine may interfere with drugs used in patients with ischaemic heart disease such as beta-blockers or calcium antagonists.
- Acitretin has a very limited anti-inflammatory potential and may induce or worsen hyperlipidaemia.

Moderate-to-severe psoriasis is associated with several well-established cardiovascular risk factors including obesity, hypertension, diabetes, dyslipidaemia and metabolic syndrome.115 Psoriasis severity has been linked to a higher prevalence of these risk factors. However, there is conflicting evidence as to whether psoriasis is associated with increased cardiovascular events and whether psoriasis itself represents an independent cardiovascular risk factor.116 Indeed, a large cohort study in Rotterdam found no difference in the risk of ischaemic heart disease hospitalizations in patients with psoriasis compared with matched control subjects.117 Stern and Huibregtse118 found that patients with very severe psoriasis have increased all-cause mortality, but that severe psoriasis is not an independent risk factor for ischaemic heart disease. The aforementioned studies are in contrast to a large and growing body of literature that suggests patients with more severe psoriasis carry a clinically relevant increased risk of mortality due to ischaemic heart disease. Samarasekera et al.119
critically evaluated 14 cohort studies and meta-analysed the magnitude of cardiovascular risk for the primary outcomes of cardiovascular mortality, stroke and myocardial infarction (MI). Increased risk was identified only in individuals with severe psoriasis (defined as requiring systemic therapy or hospital admission): the risk ratio relative to the general population was 1.37 (95% CI, 1.17–1.60) for cardiovascular mortality, 3.04 (95% CI 0.65–14.35) for MI and 1.59 (95% CI, 1.34–1.89) for stroke. The relative risks of cardiovascular disease were highest in the younger, severe psoriasis population (e.g. 3.10 [95% CI, 1.98–4.86] for MI at 30 years), and absolute risks were greatest in older individuals with severe psoriasis (e.g. 23.2 excess MIs per 10 000 person-years at 60 years). Geata et al. showed an approximately 25% increased relative risk of cardiovascular disease in patients with psoriasis, independently of smoking, obesity and hyperlipidaemia. The pooled relative risks for cardiovascular mortality in psoriasis compared with general population were 1.15 (95% CI 1.09–1.21) in all patients with psoriasis, 1.05 (95% CI 0.92–1.20) in those with mild psoriasis and 1.38 (95% CI 1.09–1.74) in severe disease. A recent systematic review and meta-analysis indicate that subclinical coronary artery disease diagnosed with cardiac computed tomography angiography is more prevalent in patients with psoriasis, with an increased burden of disease and number of high-risk coronary plaques.

It has been proposed that there may be overlapping immune pathways in both psoriasis and ischaemic heart diseases that may underlie this association. It is also a matter of great interest whether systemic antipsoriatic treatments affect cardiovascular risk by reducing the overall inflammatory burden. It is not known whether systemic treatments could modify cardiovascular outcomes including the rate of MI. However, studies investigating the effects of systemic treatments on cardiovascular risk factors including metabolic parameters (e.g. serum lipids), blood pressure or biomarkers of inflammation and atherosclerosis (e.g. C-reactive protein, endothelial dysfunction) have been completed. Multiple studies have failed to show any significant changes in metabolic parameters in patients receiving both PUVA and narrowband UVB therapy. In contrast, systemic retinoids (i.e. acitretin) commonly increase serum triglycerides and cholesterol by shifting high-density lipoproteins to low-density lipoproteins. Similarly, ciclosporin can increase serum lipids, plasma glucose and blood pressure in a dose-dependent fashion. Therapy with MTX is associated with a reduced risk of cardiovascular morbidity and mortality in patients with RA as well as in patients with psoriasis and psoriatic arthritis.

In a longitudinal cohort study of 6902 patients with psoriasis, Ahlehoff et al. found that treatment with methotrexate was associated with reduced risk of cardiovascular events compared to patients treated with other antipsoriatic therapies such as ciclosporin and retinoids. Methotrexate therapy decreases carotid intima–media thickness (a marker of arteriosclerosis) in patients with moderate-to-severe psoriasis. Preclinical and pilot studies suggest possible cardioprotective effects of apremilast and fumarates but there is no clinical evidence that affect cardiovascular risk.

The effect of biological therapies on the risk of ischaemic heart disease is unclear. Treatment with TNFi and ustekinumab has been shown to reduce aortic vascular inflammation and decrease systemic inflammatory biomarkers. Moreover, therapy with TNFi improves biomarkers of atherosclerosis by reducing either intima–media thickness and arterial stiffness in patients with RA, spondyloarthropathies, PsA and psoriasis. Secukinumab may have a beneficial effect on cardiovascular risk in patients with psoriasis by improving endothelial function measured by flow-mediated dilation.

There is conflicting evidence on the effects of biologic therapy on the incidence of cardiovascular accidents in patients with psoriasis. A large cohort study of 25 554 patients with psoriasis followed for eight years using administrative and pharmacy claims data from a large U.S. insurer (i.e. United Health Group) did not show a reduced risk of MI in those receiving systemic therapy compared to those exposed to phototherapy. A recent comparison of patients with first time hospital-diagnosed psoriasis between 1995 and 2002 (early era cohort) and those diagnosed between 2006 and 2013 (late era cohort) did not show any change in MI risk despite increased cardiovascular disease prevention and the availability of biologic therapy. A meta-analysis of 22 randomized, placebo-controlled, double-blind studies of IL-12/23 antibodies and anti-TNF-α agents comprising 10 183 adult patients evaluated the possible association between biologic therapies and major adverse cardiovascular events (MACE). Compared with placebo, there was no significant difference in the rate of MACE observed in patients receiving anti-IL-12/23 antibodies or anti-TNF-α treatments. However, the authors acknowledged that the study may have been underpowered to identify a significant difference. However, other studies have shown different outcomes. In particular, Wu et al. assessed whether patients with psoriasis treated with TNFi inhibitors had a decreased risk of MI compared with those treated with other systemic therapies, phototherapy or topical. This was a retrospective cohort study of 8845 patients, 1673 received a TNFi for at least two months, 2097 received conventional systemic treatments or phototherapy, and 5075 received only topical treatment. After adjusting for MI risk factors, the TNFi cohort had a significantly lower risk of MI compared with the topical cohort (adjusted hazard ratio, 0.50; 95% CI, 0.32–0.79). The difference in incidence of MI between TNFi and conventional systemic treatments or phototherapy was not significant. In a Danish nationwide real-world study of 2400 patients with severe psoriasis enrolled in a registry, treatment with biological agents (n = 693) or MTX (n = 799) was associated with lower cardiovascular disease event rates than treatment with other antipsoriatic therapies. This is consistent with Wu et al. who found that psoriasis patients receiving TNFis had a lower...
major cardiovascular event risk compared to those receiving methotrexate and cumulative exposure to TNFis was associated with an 11% cardiovascular event risk reduction. Concern was expressed over initial analyses linking IL-12/23 inhibitors with MACEs in the first week of therapy. However, additional meta-analysis of clinical trials and data from registries in psoriasis and psoriatic arthritis suggest that licensed biologic therapies, including TNFi (adalimumab, etanercept and infliximab), anti-IL-17A agents (secukinumab and ixekizumab) or ustekinumab, are not associated with MACEs. In a large prospective cohort study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), there were no significant differences in the risk of major cardiovascular events between etanercept, adalimumab, ustekinumab and methotrexate. Similarly, in 60,028 patients with psoriasis or psoriatic arthritis from multiple US databases, no significant difference was found in the risk of MACEs after initiation of therapy with TNFi or ustekinumab.

a. Heart failure

Summary/key points

- Heart failure (HF) is a clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary cracks and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.
- Common causes include coronary artery disease (previous myocardial infarction), arterial hypertension, atrial fibrillation, valvular heart disease and cardiomyopathies. The condition may, therefore, co-exist with ischaemic heart disease.
- Patients with suspected or confirmed heart failure should be referred to a cardiologist for investigation and treatment in accordance with current European Society of Cardiology guidance.
- The NYHA functional classification is commonly used to describe the severity of symptoms and exercise intolerance in patients with heart failure. (https://manual.jointcommission.org/releases/TJC2018A/DataElem0439.html)

We suggest against using cyclosporine in patients with psoriasis and advanced congestive heart failure.

We suggest that methotrexate, acitretin and apremilast are considered as treatment in patients with psoriasis and advanced congestive heart failure.

We suggest that ustekinumab, inhibitors of IL-17 and of IL-23 are considered as treatment in patients with psoriasis and advanced congestive heart failure.

We recommend against using anti-TNFs in patients with psoriasis and advanced congestive heart failure.

We recommend discussing the choice of a systemic therapy in psoriasis patients with advanced congestive heart failure with a cardiologist.

We suggest that TNF-α in heart failure (HF) stems from the observations that TNF-α exerts negative inotropic effects and is capable of promoting fibrosis, hypertrophy and cardiomyopathy in animal models. Moreover, cardiac-specific TNF-α levels are regulated by pressure and volume load in animals and in humans. Therefore, a small series of clinical trials was conducted with TNFi to investigate its potential beneficial effects in patients with HF. Both RENAISSANCE and RECOVER were large, multicentre, randomized, double-blind, placebo-controlled trials of
etanercept in HF. Both studies failed to show improved mortality or decreased hospitalizations due to CHF. The key finding of the RENAISSANCE trial was a trend towards higher mortality in etanercept-treated subjects, a concern heightened by the apparent dose–response relationship. The combined analysis of these studies showed a trend towards increased mortality and/or HF hospitalizations in the combined twice-weekly/thrice-weekly etanercept group compared with placebo.\textsuperscript{159,160} Infliximab was evaluated in a phase II randomized, double-blind, placebo-controlled pilot study.\textsuperscript{161} This pilot study did not show any beneficial effect of infliximab over placebo in terms of efficacy. Higher-dose infliximab (10 mg/kg) was associated with an increase in both all-cause mortality and the number of hospitalizations due to HF at weeks 28 and 54. In summary, the results of randomized, placebo-controlled trials with both etanercept and infliximab suggest a deleterious effect of higher doses of TNF blockers in patients with NYHA class III or IV HF. In particular, there was a trend towards higher mortality and a greater number of hospitalizations for HF. However, a recent Cochrane systematic review including 163 randomized controls trials with 50 010 participants and 46 extension studies with 11 954 participants found that the rate of new diagnosis of HF was not statistically significantly different between those patients treated with biologics and control treatments.\textsuperscript{162} The cardiovascular safety data extracted from 74 articles, corresponding to 77 randomized controlled trials of TNF, anti-IL-12/23, anti-IL-23 and anti-IL-17 agents for the treatment of psoriatic arthritis or psoriasis showed no significant difference in CHF incidence in patients receiving biological agents in comparison with placebo.\textsuperscript{153} In conclusion, only moderate-to-severe CHF is a concern for initiating TNFi therapy in patients with psoriasis.

3.7 Kidney disease: How should psoriasis patients with kidney failure/renal impairment be managed?

Narrative review of the existing literature was conducted.

Results/Answer A number of risk factors that predispose to chronic kidney disease (CKD) are especially prevalent in people with multiple comorbidity including diabetes, hypertension, cardiovascular disease being treated with drugs that may impair kidney function. A UK population-based study suggests that the risk of CKD was increased in people with moderate-to-severe psoriasis, independent of these risk factors.\textsuperscript{163} Thus, the optimal choice of systemic therapy in the context of CKD is likely to be a relatively common clinical scenario. This is supported by data from the Spanish long-term pharmacovigilance registry indicating that 13% of the total cohort were categorized as having ‘chronic renal failure’.\textsuperscript{164}

In people with established CKD, the following factors were considered when evaluating the treatment options for psoriasis:

- the likely effect of the psoriasis treatment on residual kidney function
- the impact of CKD on pharmacokinetics/pharmacodynamics of the psoriasis treatment
- potential drug interactions
- associated CKD comorbidity

Systemic therapies Acitretin. National guidelines in the UK,\textsuperscript{165} United States,166 Spain\textsuperscript{167} all recommend avoiding acitretin in moderate-to-severe renal disease, although no evidence is cited underpinning these recommendations. There were no studies identified that specifically address the use of acitretin for psoriasis in the context of CKD. Acitretin is widely used in the renal transplant population for skin cancer prophylaxis where stage 3 CKD is common; a recent systematic review in this population showed no increased in AEs when compared to placebo.\textsuperscript{168} Limited data from RCTs do not indicate acitretin is a nephrotoxic drug. Acitretin is highly lipophilic, penetrates readily into body tissues and is highly protein (albumin) bound. Hypoalbuminaemia in association with CKD may therefore potentially increase drug clearance. It is metabolized in the liver to 13-cis acitretin and etretinate and then undergoes glucuronidation into inactive, water-soluble forms. In health, acitretin is excreted entirely in the form of these inactive metabolites, in approximately equal parts via the kidneys and the bile. In a single report,\textsuperscript{169} the mean areas under the plasma concentration versus time curves of acitretin and 13-cis acitretin following a single oral dose of 50 mg of acitretin in six patients on haemodialysis were, in fact, about 50% lower than healthy controls. No retinoids were detectable in the dialysate.

In summary, acitretin is not known to be nephrotoxic and CKD (any stage) would not be predicted to markedly impact on drug disposition.

Apremilast. Apremilast has no known nephrotoxic potential. In the pivotal clinical trials, there was no evidence for treatment emergent adverse events related to renal function.\textsuperscript{74,170} In patients with mild-to-moderate impairment of kidney function, no dose adjustment of apremilast is necessary. When patients have severe impairment of kidney function (eGFR below 30 mL/min/1.73 m\textsuperscript{2} or CLcr < 30 mL/min), the dose of apremilast should be reduced to 30 mg once daily. When starting treatment with apremilast in case of severe renal insufficiency, only the morning dose should be given as total daily dose (recommendations according to SmPC).

Fumarates. Fumarates are known to be potentially nephrotoxic and may rarely cause an irreversible, proximal renal tubular nephropathy with long-term use. Recent studies\textsuperscript{571} of dimethyl fumarate (for MS) confirm proteinuria and reduction in eGFR to occur more commonly than placebo; German guidelines and the SmPC specify careful monitoring of serum creatinine, and treatment cessation in the event of significant change. In health, fumarates are extensively metabolized by ubiquitous esterases,
Ciclosporin. Ciclosporin has established nephrotoxic potential. Acute nephrotoxicity can occur within weeks of treatment initiation, is reversible and arises due to dose-dependent vascular dysfunction, involving afferent arteriolar constriction that leads to increased vascular resistance and a decrease in glomerular filtration rate. Tubular dysfunction may also occur, characterized by decreased magnesium re-absorption, decreased uric acid excretion, decreased potassium and hydrogen ion secretion, and distal tubular acidosis. Chronic nephrotoxicity is largely irreversible and is characterized by progressive arteriolar hyalinosis, interstitial fibrosis, tubular atrophy and glomerular sclerosis. Chronic nephrotoxicity is more likely to occur with higher daily doses, larger cumulative doses and long-term therapy (more than 1–2 years). In one long-term psoriasis study, patients with a pre-treatment creatinine of >100 µmol/L were more likely to discontinue therapy. In a study performed in patients with (stage 5) terminal renal failure, the systemic clearance was approximately two thirds of that in patients with normally functioning kidneys. Less than 1% of the administered dose is removed by dialysis.

Guidelines recommend using CsA with caution in people with CKD; in those with significant reduction in renal function (CKD stage 3 or more,176 CsA nephrotoxicity may lead to further critical reduction in function.

Methotrexate. MTX is not generally considered nephrotoxic when used at low doses for inflammatory disease, although renal impairment is reported177 and may be an under-recognized event. MTX and 7-hydroxymethotrexate are mainly excreted through the kidneys, via glomerular filtration and active transport. Methotrexate clearance is therefore reduced (and thus risk of toxicity increased) in the context of CKD, depending on the stage. In a cohort of 77 patients with RA and various stages of CKD, the elimination half-life of a single dose of intramuscular MTX (7.5–15 mg) was directly related to GFR, with a decrease in MTX of 44.7% in the category of patients with the poorest renal function (i.e. creatinine clearance <45 mL/min, roughly equivalent to stage 3b).178 Pooling data from RCTs of MTX for RA also indicate that presence of renal impairment (creatinine clearance <79 mL/min) increases the OR for severe and pulmonary toxicity by four compared to those with a creatinine clearance >99.8 mL/min (reference group).179 There are no studies evaluating use of MTX for psoriasis with CKD. US guidelines166 consider renal impairment a relative contraindication to MTX, and all recent RCTs with a MTX arm exclude patients with 'significant' renal impairment. There are several case reports of life-threatening toxicity following MTX use in people on dialysis (reviewed in Ref. [180]). Guidelines in the rheumatology literature, largely consequent on the two studies referenced above, recommend avoiding MTX in people with creatinine clearance of <20 mL/min and to halve the dose in those between 20 and 50 mL/min (summarized in Ref. [181]).

Biological therapy To date, nephrotoxicity has not been reported as an AE in relation to all groups of biologic agents (TNF antagonists, IL-17A/IL-17RA antagonists, IL-12/23p40 and IL-23p19 antagonists). Clearance of biological therapies should not be affected in case of CKD (of any stage).

3.8. Neurological diseases: Which treatments are appropriate for psoriasis patients with neurological diseases?

Narrative review of the existing literature was conducted.

Results/Answer Standard systemic therapy. Ciclosporin—Neurotoxicity is a well-established complication of CsA although receives surprisingly little attention in literature. A comprehensive review182 referencing data from (primarily) the transplant population estimated that 10% and 28% of patients receiving calcineurin inhibitors experience neurotoxic side-effects ranging from mild paraesthesia and peripheral neuropathy through to centrally mediated complications such as altered cognition, visual disturbances and seizures. Of these tremor and paraesthesia are the most common, and in the early trials in psoriasis, affected 40% and 25% of participants receiving 5 mg/kg,
Calcineurin is a major component of neural tissue and plays a key role in the regulation of nerve cell function and neurotransmission; toxicity is dose-dependent and largely reversible. Ciclosporin does not readily cross the blood–brain barrier, so conditions that disrupt the integrity of this, such as neurodegenerative disease, systemic infections or hypertension, may perhaps also make patients more prone to the neurotoxic effects of CsA. Additional factors such as CaA-related hypomagnesaemia may also contribute. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with CsA for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contraindication to treatment.

**Fumarates**—Dimethyl fumarate (DMF) has more recently been licensed and developed for use in psoriasis and is also a licensed treatment for MS (reviewed in Ref. [187]) at doses of 240 mg BID. Fumarates may be a preferred option for the treatment of psoriasis in people with established MS. There have been a total of nine reports of confirmed progressive multifocal leukoencephalopathy (PML) in patients with psoriasis treated with fumarates; six with Fumaderm, two with Psorinovo (a slow-release DMF formulation) and one with compounded fumaric acid esters. In all cases, a degree of lymphopenia and/or other contributory factors for PML is thought to have been of direct aetiological relevance.

**Methotrexate**—CNS toxicity is a well-recognized AE of high dose MTX, especially with intra-thecal administration. Low-dose oral and s/c MTX have rarely been reported to cause a reversible leukoencephalopathy (see Ref. [197,198] for recent reports and reviews). The SmPC cites drowsiness, ataxia, blurred vision, transient subtle cognitive dysfunction, mood alteration and unusual cranial sensations as occasionally reported with low-dose MTX. No studies were identified specifically reporting on outcomes in people with pre-existing neurological disease treated with MTX for psoriasis. Existing guidelines and the SmPC do not stipulate neurological disease to be a contraindication to treatment.

**Biological therapy TNF antagonists.** In vitro, murine and human data suggest that TNF has an important role in the pathogenesis of inflammatory demyelinating disease (reviewed in Ref. [199]). However, an early report of increased lesion activity in two MS patients receiving infliximab as well as the withdrawal of lenecrecpt (a soluble p55 receptor developed for the treatment of MS) due to increasing severity and duration of symptoms in clinical trial subjects led to heightened awareness of potential risk of TNF antagonist therapy in the context of MS. More recently, the single nucleotide polymorphism (SNP) rs1800693 in the TNFRSF1A gene associated with MS but not psoriasis (or other autoimmune conditions) has been shown to direct expression of a novel, soluble form of TNFR1 that can block TNF, hence lending further biological plausibility to a causal relationship between TNF antagonism and demyelination.

All five TNF antagonists have been associated with aggravation of MS and/or new-onset central demyelination which have been reviewed by Mahil et al. Case reports in more recently licensed anti-TNF agents golimumab and certolizumab have been described. Of 84 cases of central demyelination reported in patients with psoriasis, the majority occurred within the first year of therapy; 33% (25/76) achieved complete recovery after cessation of anti-TNF +/- adjunctive therapy, 72% (55/76) did not achieve complete clinical recovery after cessation of TNF antagonist therapy. There were fourteen cases of worsening neurological disease despite cessation of anti-TNF therapy and several reports of new, clinically silent lesions detected on follow-up imaging. A case–control study in rheumatoid arthritis using a Canadian administrative claims and electronic medical records database showed a trend towards an increased rate of demyelination in 891 patients with no risk factors (for demyelination) with the authors suggesting that TNF antagonist therapy may increase risk of truly incident demyelinating events by ~30%, although failed to meet statistical significance (adjusted rate ratio 1.31 [95% CI 0.68–2.50]). To date, trial and pharmacovigilance registry data have not shown any increased risk although this may relate to a low overall incidence, as well as exclusion of people at particular risk.

With respect to peripheral disease, all forms of demyelinating neuropathies, including Guillain–Barre syndrome, Miller–Fisher syndrome, multifocal motor neuropathy with conduction blocks, Lewis–Sumner syndrome and chronic polyradiculoneuropathy have been reported in association with TNF antagonist therapy, although numbers of case reports in the literature are fewer when compared to central demyelination. One report of five patients providing longer-term data (up 3–4 years) indicated that once triggered, chronic demyelinating neuropathy may persist or recur irrespective of whether the TNF antagonist is discontinued. Isolated cases of axonal neuropathy and vasculitic neuropathy are also reported. US, UK and German psoriasis guidelines all advise avoidance or caution with TNF antagonists in people with demyelination and caution in those at risk.

**IL-12/23 pathway inhibitors.** The IL (interleukin)-12 p40 family of cytokines (IL-12 and IL-23) has been strongly implicated in the pathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), an animal model that mimics many clinical and histological characteristics of MS. This prompted a phase II study evaluating the role of ustekinumab in patients with relapsing and remitting MS. Patients were randomly assigned 1:1:1:1:1 to placebo or 27 mg, 90 mg...
or 180 mg ustekinumab every four weeks or 90 mg ustekinumab every eight weeks up to week 23. A total of 200 patients received at least one dose of ustekinumab and while there was no evidence of benefit, there was no evidence of worsening neurological disease or increase in AEs when compared to placebo. To date, there has been one case report of primary progressive MS in a patient taking ustekinumab for refractory Crohn’s disease220 with the first neurological symptoms occurring around one year into therapy. She had received TNF antagonist therapy (infliximab, adalimumab and certolizumab) prior to ustekinumab. With respect to peripheral demyelinating disease, a single case of Guillain–Barré has been reported in a 23-year-old man with refractory Crohn’s disease one year after commencing treatment with ustekinumab, having previously been treated with adalimumab.221 A further isolated case of peripheral neuropathy of unspecified aetiology after three doses of ustekinumab was reported in an observational, retrospective 5-year follow-up study of ustekinumab in psoriasis.222 Furthermore, the first case of reversible posterior leukoencephalopathy syndrome (RPLS) in a 65-year-old woman who received ustekinumab for over 2.5 years for psoriasis has been reported. She presented with mild hypertension, confusion, headache, nausea, vomiting, multiple seizures and computed tomographic scans and magnetic resonance images of her head revealed characteristic findings of RPLS. Complete clinical recovery and reversal of the radiologic findings occurred, which is also considered typical of RPLS.223 No data on the newer p19 inhibitors were identified.

II-17 inhibitors. The IL-17A/F pathway is implicated in both psoriasis and multiple sclerosis, with elevated levels of IL-17A and IL-17F levels detected in both diseases.224 Phase II randomized controlled data have shown encouraging results with secukinumab associated with a reduction in both the number of active and new MRI brain lesions in patients relapsing–remitting MS which were reduced by 49% and 67%, respectively,225 but this is yet to be replicated in further studies. There are five cases in the literature of patients receiving secukinumab for immune-mediated inflammatory diseases with concomitant MS. 80% (4/5) of patients with MS remained stable with no progression of disease and achieved remission of psoriasis/psoriatic arthritis/ankylosing spondylitis. 20% (1/5) had a relapse of MS and required treatment with rituximab.226–228 There are no reported de novo cases of central demyelination with secukinumab; however, longer-term safety data are required. No data on other IL-17 agents (ixekizumab, brodalumab) were identified.

Summary and synthesis of recommendations. With the exception of TNF antagonists, any of the standard or biologic treatments can be used in people with co-existing neurological disease. Although neurotoxicity is reported with CsA, and (rarely) with MTX, there is no evidence that those with pre-existing neurological disease are more at risk. The causal association between TNF antagonists and demyelination remains to be proven although accumulating anecdotal reports, biological plausibility and expert consensus indicate that this class of drugs should be avoided in patients with a clear history of central demyelination. Given evidence for a genetic basis to MS230 and that asymptomatic first-degree relatives may have morphological evidence of subclinical disease and/or CSF oligoclonal bands (reviewed in Ref. [231]), it would seem prudent to use TNF antagonists with caution in this group too. Dimethyl fumarate is licensed for use in MS and so may be a preferred first-line option; however, surveillance monitoring of peripheral leucocyte counts is strongly recommended in order to minimize the risk of PML. Ustekinumab p19 and anti-IL-17 represent alternative treatment options.

3.9. Viral hepatitis: When and how should psoriasis patients be screened for viral hepatitis and how should patients who test positive be managed?

| We suggest using fumarates in psoriasis patients with multiple sclerosis. | Strong consensus\(^1\) |
|---|---|
| We recommend against using TNF antagonist therapy in psoriasis patients with a diagnosis of multiple sclerosis or other demyelinating disease. | 100% agreement |
| In psoriasis patients with a first degree relative with multiple sclerosis or other demyelinating disease, we suggest against the use of TNF antagonist therapy if other suitable treatment options are available. | EXPERT CONSENSUS |

\(^1\)Due to personal-financial conflict of interest 3 abstentions

A systematic review was conducted, see Methods & Evidence Report.

Results/Answer

The available data published are insufficient to give strong recommendations for or against using the available antipsoriatic drugs in patients with moderate-to-severe psoriasis and concomitant hepatitis B. Table 4 offers a summary of reported cases of reactivation. Reported cases need to be seen in correlation to approval date, especially with years and numbers of psoriasis patients with hepatitis

JEADV 2021, 35, 281–317 © 2020 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology
exposed to the drug. For detailed information, see methods report.

1Reported cases need to be seen in correlation to approval date, especially with years and numbers of psoriasis patients with hepatitis exposed to the drug. For detailed information, see methods report.

For some of the treatments, hepatitis is mentioned as a contraindication in the SmPC, although clinical practice, available case series or registry data may indicate a safety profile in line with treatments where this is not mentioned as a contraindication. This holds particularly true for methotrexate, where study data indicate at least no increase in liver fibrosis.232

We recommend screening for hepatitis A as a routine measure before starting a systemic treatment. Strong consensus

We recommend screening patients for hepatitis B (HBsAg, anti-HBsAg, anti-HBcAg) as a routine measure before starting a treatment with cyclosporine, methotrexate or biologics. Strong consensus

We recommend to follow the algorithm presented in fig. 1 for the interpretation of the hepatitis B test results. Strong consensus

We recommend screening patients for hepatitis C as a routine measure before starting a treatment with methotrexate or biologics. Strong consensus

In case of positive findings for hepatitis C, we recommend referral to a hepatologist. Strong consensus

We recommend against screening for hepatitis A as a routine measure before starting a systemic treatment. Strong consensus

We recommend screening patients for hepatitis B (HBsAg, anti-HBsAg, anti-HBcAg) as a routine measure before starting a treatment with cyclosporine, methotrexate or biologics. Strong consensus

We recommend to follow the algorithm presented in fig. 1 for the interpretation of the hepatitis B test results. Strong consensus

We recommend screening patients for hepatitis C as a routine measure before starting a treatment with methotrexate or biologics. Strong consensus

In case of positive findings for hepatitis C, we recommend referral to a hepatologist. Strong consensus

1Due to personal-financial conflict of interest 2 abstentions

Choice of treatment

We recommend that treatment decision for patients with positive test result for HBsAg or positive HBV DNA should always be taken together with a hepatologist. Strong consensus

Depending on the individual health care setting and personal experience and training, we suggest to consult with a hepatologist to choose a systemic treatment for patients that have a positive anti-HBc with a neg. HBsAG/HBV-DNA test. Strong consensus

We suggest, based on the common practice within the guideline group, acitretin, apremilast, fumarates, MTX, ustekinumab and the anti-IL 17 and anti-IL 23 antibodies as preferred systemic treatment options for this patient group. Strong consensus

We recommend regular testing for HBsAg/HBV-DNA (e.g. every three months) during systemic treatment. Strong consensus

We recommend to record all treatment initiations and follow up visits of psoriasis patients with concomitant hepatitis B or C cases in drug registries. Strong consensus

1Due to personal-financial conflict of interest 2 abstentions
Figure 1  Algorithm for the interpretation of the hepatitis B test results.

**Table 4** Risk of hepatitis B reactivation during psoriasis treatment

| Systemic treatments     | Case of hepatitis B reactivation during psoriasis treatment identified in systematic search |
|-------------------------|---------------------------------------------------------------------------------------------|
| **Conventional systemic agents** |                                                                                             |
| Acitretin               | No                                                                                          |
| Ciclosporin             | No                                                                                          |
| Fumarates               | No                                                                                          |
| Methotrexate            | No                                                                                          |
| **Small molecules**     |                                                                                             |
| Apremilast              | No*                                                                                          |
| **Anti-TNF alpha**      |                                                                                             |
| Etanercept              | Yes (see methods report for details)                                                         |
| Infliximab              | Yes (see methods report for details)                                                         |
| Adalimumab              | Yes (see methods report for details)                                                         |
| Certolizumab            | ?                                                                                            |
| **Anti-IL 12/23**       |                                                                                             |
| Ustekinumab             | Yes (see methods report for details)                                                         |
| **Anti-IL 17**          |                                                                                             |
| Secukinumab             | Yes (see methods report for details)                                                         |
| Ixekizumab              | No*                                                                                          |
| Brodalumab              | No*                                                                                          |
| **Anti-IL 23**          |                                                                                             |
| Gusekumab               | No*                                                                                          |
| Tildrakizumab           | No*                                                                                          |
| Risankizumab            | No*                                                                                          |

*Reported cases need to be seen in correlation to approval date, especially with years and numbers of psoriasis patients with hepatitis exposed to the drug. For detailed information, see methods report.
Tuberculosis screening

Diagnostic for TB, regardless Bacillus Calmette-Guérin (BCG) vaccination, prior to and during follow up with biologic. One must be alert for TB infections during biologic treatment to six months after discontinuation. During treatment, rescreening for LTBI is recommended and frequency should be based on: anamnesis, risk of exposure, as well as tuberculin skin test (TST) and interferon gamma release assay (IGRA) results.

1. Anamnesis:
   - Symptoms suspicious for TB
   - History of TB, adequate treatment
   - Exposure to TB
   - Origin from or recently stayed for a long time in an endemic area
   - High risk patient
   - BCG vaccination

2. Physical examination, to consider:
   - Auscultation of the lungs if symptomatic (not-specific for TB diagnosis)
   - Scar (left) upper arm (may indicate a BCG vaccination)
   - Enlarged lymph nodes, abscess scars

3. Chest X-ray: (If the chest X-ray has been performed more than 3 months ago, a new chest X-ray is required.)
   - Suspicious for active, LTBI or history of TB?
     → Consult pulmonologist if abnormalities

4. TST* and/or IGRA
   - If IGRA and TST are performed, the IGRA can best be drawn right after the TST is assessed. If drawing is done more than three days after the TST, the TST can booster the IGRA and result in a false-positive response.
   - The recommendation to perform IGRA testing rather than TST testing is strong for those who have received the BCG vaccination.

*It is necessary to follow the local recommendations, as the threshold for the TST is different among countries and even among regions within the same country. In most of the countries ≥ 5 mm is considered positive

| TST* | IGRA | Diagnosis | Policy |
|------|------|-----------|--------|
| <5 mm | negative | Depends on anamnesis | If no TB suspicious anamnesis or symptoms, no history of TB, no TB exposure, not from or recently from an endemic area, and no high risk patient, a biologic can be applied. |
| ≥5 mm <10 mm | negative | LTBI or active TB with false negative IGRA, or false positive TST | Consult pulmonologist for any further diagnosis and treatment |
| >10 mm | negative | Strongly consider LTBI or active TB with false negative IGRA, or false positive TST | Consult pulmonologist for treatment |
| Every result | QFT-G 0.2-0.35 U/ml | Consider LTBI or active TB, or IGRA false positive | Consult pulmonologist for any further diagnosis and treatment |
| Every result | Positive (QFT-G > 0.35 U/ml) | Strongly consider LTBI or active TB | Consult pulmonologist for treatment |

*It is necessary to follow the local recommendations, as the threshold for the TST is different among countries and even among regions within the same country. In most of the countries ≥ 5 mm is considered positive

3.10. Tuberculosis: How to screen for tuberculosis before and during biologic treatment?

This chapter is based on the related chapter in previous versions of this guideline.7,8 A systematic search was conducted, details of which can be found in the Methods & Evidence Report.

Results/Answer Current guidelines and recommendations for screening for tuberculosis (TB) vary between countries and specialities. There are variations in the recommended diagnostic tests, cut-off values, follow-up and preventive therapy regimens. A uniform approach for the diagnostic procedures and the interpretation of the test results for latent tuberculosis infection (LTBI) screening may reduce the cases of reactivation, but giving binding pan-European recommendations is partly hampered by different regional regulations. For recommendation for which treatment TB screening is recommended, please see respective drug chapters.

Tuberculin skin test (TST) False-negative TST includes those related to the protein purified derivative (PPD) (PPD expiration, experience or loss of antigen [e.g. subcutaneous administration]), and those related to the situation of the patient (HIV infection, recent infections and vaccinations, malignancy, metabolic diseases, immunosuppressant therapy or extreme ages [newborn, elderly]). False-positive TST includes those related to the administration and PPD lecture (inexperience, high amount of antigen) and cross-reactions (BCG vaccination and most environmental
non-tuberculous mycobacteria). Although a BCG vaccination or an atypical mycobacterial infection may cross-react with the TST, causing a false-positive result, the tuberculin reaction would usually be much higher if active TB is truly present. The BCG vaccination may fade over time and no cross-reaction would occur. Regardless the BCG vaccination, in general, an assessment of ≥5 mm induration will be considered as positive. A patient may then be referred directly to the pulmonologist. In patients with a history of BCG vaccination, IGRA testing is preferred over TST. IGRA IGRA is a specific blood test. After a Mycobacterium Tuberculosis infection, T cells will release interferon-gamma (IFN-\(\gamma\)) in response to contact with the TB antigens. Two measurements for interferon-gamma are known; the QuantiFERON\(^\text{®}-\)TB Gold test (QFT-G), based on the amount of IFN-\(\gamma\) that is released in response to the antigens, and the T-SPOT\(^\text{®}-\)TB test (T-SPOT), counting the number of T cells that produce IFN-\(\gamma\) in a sample of blood. The IGRA is not affected by prior BCG vaccination; however, the interpretation of results (borderline results) might be limited due to issues in the cut-off values, shifting conversions and reversion rates over time, and varying test reproducibility. Neither TST or IGRA allows to distinguish between active or latent TB.\(^\text{233}\) A suppressed immune system reduces the sensitivity of tests based on T-cell responses. Only positive results will be convincing in that case, while negative results cannot rule out a TB infection. A negative IGRA, following a positive TST, can still suggest a LTBI. Besides, the IGRA can be unreliable (false negative) if other immunosuppressive medication was applied in advance. An IGRA is also recommended if the TST was less than 5 mm induration. Negative results of TST or IGRA of HIV-infected patients with a low CD-4 count cannot rule out a TB infection.

**Screening during biologic treatment** Physicians have to be aware that there is still a risk of active tuberculosis under biologic therapy, even if LTBI was correctly treated. Therefore, rescreening on LTBI is preferable during biologic treatment. The frequency should take risk exposure into consideration. Besides medical history, both TST and IGRA are recommended, because of the influence that the biologic may have (false-negative) on these tests. A high index of suspicion should also be maintained for 6 months following discontinuation.

### 3.11. Tuberculosis: How to manage psoriasis in patients with positive tuberculosis test results?

This chapter is based on the related chapter in previous versions of this guideline.\(^7\) A systematic search was conducted, the details of which can be found in the Methods & Evidence Report.

#### Results/Answer

Comment: Depending on the prevalence of TB and on the healthcare situation, dermatologists may be in a position to interpret positive findings and to make further decisions regarding immunosuppressive therapies. We recommend to discuss the decision to initiate immuno-suppressive therapies in patients with signs for latent tuberculosis case-by-case with an infectious disease specialist. As a commonly used procedure in case of latent TB, a treatment with isoniazid can be recommended with treatment initiation one month before the start of the immunosuppressive therapy and should be continued for 6 months (for alternatives see Table 5).

### Table 5 Therapeutic regimens for LTBI

| Drug | Dose | Treatment duration |
|------|------|--------------------|
| INH alone (daily) | 5 mg/kg; max dose: 300 mg | 6–9 months |
| RIF alone (daily) | 10 mg/kg; max dose: 600 mg | 3–4 months |
| INH + RIF (daily) | INH: 5 mg/kg; max dose: 300 mg | 3–4 months |
| | RIF: 10 mg/kg; max dose: 600 mg | |

INH, isoniazid; RIF, rifampicin, treatments with pyrazinamide should be avoided (high risk of hepatotoxicity). Based on WHO: Latent tuberculosis infection: updated and consolidated guidelines for programmatic management, 2018.
management decisions themselves or direct referral to infectious disease specialists with interdisciplinary cooperation may be common.

**Interpretation of positive findings in IGRA/TST.** Patients with active and latent tuberculosis (TB) can be identified using either the interferon-gamma release assay (IGRA) or tuberculin skin test (TST). However, neither test can distinguish between the latent and active states of the disease.\(^{233}\) IGRA is a specific blood test. The interpretation of IGRA test results (especially borderline results) can be limited due to issues in the cut-off values, shifting conversions and reversion rates over time and varying test reproducibility. In case of borderline results, repeating the test may be advisable.\(^{233}\) The sensitivity of TST for latent tuberculosis infection (LTBI) has been described as 74% and the specificity of 89% in a meta-analysis.\(^{234,235}\) The positive predictive value for TB infection by the TST depends on the prevalence of TB within a given region/population and the possibility of cross-reactions.\(^{234,235}\) The positive predictive value for TB infection by the TST depends on the prevalence of TB within a given region/population and the possibility of cross-reactions.\(^{234,235}\) False-positive TST includes those related to the administration of purified protein derivative (PPD) and its lecture (inexperience, high amount of antigen) and cross-reactions (BCG vaccination and most environmental non-tuberculous mycobacteria). Although the TST would usually be, much higher if active TB is truly present.

Means to distinguish between active and latent TB commonly used in the guidelines group experts’ setting include medical history (exposure risk), signs and symptoms (e.g. current cough, fever, weight loss, night sweats), chest X-ray,\(^{236}\) and urinalysis (pyuria).\(^{237–239}\) For details of differential diagnosis of latent versus active TB, please see respective guidelines and reviews.\(^{233,236,240}\)

**Table 6** LTBI screening indication based on different systemic treatments

| Systemic treatments                  | SmPC | Comments                                      |
|--------------------------------------|------|-----------------------------------------------|
| Conventional systemic agents         |      |                                               |
| Acitretin                            | No   | No cases of reactivation have been reported\(^{246}\) |
| Ciclosporin                          | No   | Cases have been reported in organ transplant patients with high doses of CsA\(^{246}\) |
| Fumarates                            | No   | No cases of reactivation have been reported\(^{247,248}\) |
| Methotrexate                         | √    | Cases of reactivation have been reported\(^{249}\) |
| Small molecules                      |      |                                               |
| Apremilast                           | No   | Increased risk has not been reported\(^{250}\) |
| Anti-TNF alpha                       |      |                                               |
| Etanercept                           | √    | Increased risk of reactivation has been reported\(^{251,252}\) |
| Infliximab                           | √    | Increased risk of reactivation has been reported\(^{251,252}\) |
| Adalimumab                           | √    | Increased risk of reactivation has been reported\(^{251,252}\) |
| Certolizumab                         | √    | Increased risk of reactivation has been reported\(^{246,251}\) |
| Anti-IL-12/23                        |      |                                               |
| Ustekinumab                          | √    | Uncertain risk of reactivation (cases have been reported)\(^{246,253}\) |
| Anti-IL-17                           |      |                                               |
| Secukinumab                          | √    | Increased risk has not been reported in clinical trials\(^{253}\) |
| Ixekizumab                           | √    | Increased risk has not been reported in clinical trials\(^{253}\) |
| Brodalumab                           | √    | Increased risk has not been reported in clinical trials\(^{253}\) |
| Anti-IL-23                           |      |                                               |
| Guselkumab                           | √    | Increased risk has not been reported in clinical trials\(^{254}\) |
| Tildrakinumab                        | √    | Increased risk has not been reported in clinical trials\(^{255}\) |
| Risankizumab                         | √    | Increased risk has not been reported in clinical trials\(^{256}\) |

Reported cases need to be seen in correlation to approval date, especially with years and numbers of psoriasis patients exposed to the drug.

**We recommend against** TNF alpha antagonists as a treatment for patients with latent TB unless there are no other suitable treatment options.\(^1\)

**We recommend** remaining alert to signs and symptoms of tuberculosis activation or re-infection during therapy.\(^2\)

**We suggest** acitretin, apremilast or fumarates or a treatment from the anti-IL 17 and anti-IL 23 group for patients with latent TB that require a systemic antipsoriatic treatment.\(^3\)

---

\(^1\)Due to personal-financial conflict of interest 4 abstentions

\(^2\)100% agreement

\(^3\)EXPERT CONSENSUS
recommended in the summary of products characteristics (SmPC). The sensitivity of IGRA and TST may be influenced by conventional immunosuppressive treatments, so doing IGRA initially may be beneficial if a later switch, specially from MTX to other drug categories appears likely.243

Biologics. A higher risk of latent TB reactivation with infliximab and adalimumab, followed by etanercept has been identified. Cases of latent TB reactivation with ustekinumab have been reported in a long-term study of up to 5 years.151 The risk of latent TB reactivation seems to be lowest during treatment with anti-IL-17 and anti-IL-23 targeted treatments.43,244

In a systematic review by Snast et al., 78 patients who developed active TB during biologic treatment were analysed. Eighty per cent of all cases were treated with adalimumab or infliximab; 12% were treated with etanercept. No case of active TB was identified with the anti-interleukin 17 agents (ixekizumab, secukinumab and brodalumab). However, the total patient exposure years for these at the time of analysis were much shorter than for the TNF antagonists. All patients in this review had initially been screened for TB. In the majority of cases, patients had no risk factors for primary TB and active TB and presented mostly with extra-pulmonary disease within the first six months of biologic therapy.245

Table 6 provides an overview of the screening practice based on reactivation risk during antipsoriatic treatments. The risk assessment may be biased due to the different time periods when the cases occurred. At the time of TNF alpha introduction, TBC screening was not always done, leading to higher numbers of patients with TB being exposed to the respective drugs. In addition to the reported cases of TB reactivation, pathophysiological considerations of the immune response to TB favour the group of anti-IL-17 and anti-IL-23 as treatment options. IL-12 has been reported to play a role in the anti-TB immune response.

3.12. Wish for child/pregnancy: How should psoriasis patients with a wish for pregnancy in the near future or who are pregnant be managed?

This chapter is based on the related chapter in previous versions of this guideline.78 A systematic search was conducted, details of which can be found in the Methods & Evidence Report.

Results/Answer Psoriasis commonly affects men and women planning conception and women who are pregnant, so understanding the risks of therapy during conception and pregnancy is crucial. Psoriasis is not known to have a significant impact on either male or female fertility. Although pregnancy has an unpredictable effect on psoriasis, limited evidence suggests that psoriasis usually improves; around 55% improve during pregnancy, 25% report no change, and 25% worsen.257,258 Conversely in the postpartum period, psoriasis is more likely to flare; around 65% worsen; 25% demonstrate no change and 10% improve.

Maternal and fetal health outcomes are vital considerations when deciding on the optimal treatment for individuals with psoriasis who are planning conception or are pregnant. Although data are limited and not always consistent across studies, untreated severe psoriasis in the mother may be detrimental for fetal well-being and pregnancy outcomes; for example, it has been shown to be associated with preterm birth and low birthweight babies.260,261 The risk of untreated psoriasis of the mother in pregnancy must therefore be weighed against any potential harm through drug exposure of the fetus. Other factors that may impact pregnancy outcomes include alcohol consumption, smoking and comorbidities such as obesity and depression (which are more prevalent in greater disease severity).262 Despite the rapidly increasing number of medications available for the treatment of psoriasis, knowledge on their safety in pregnancy remains limited.

Non-biologic systemic drugs Acitretin. Acitretin is teratogenic and is contraindicated in women of childbearing potential, those planning pregnancy, breastfeeding or not capable of using contraception until 3 years after cessation of therapy.263

Apremilast. There are limited data about the use of the small molecule inhibitor apremilast during pregnancy. Previous studies on animals did not show an increase in malformations with apremilast, but have shown dose-related fetal loss and reduced birth weight. Apremilast is therefore contraindicated during pregnancy.264 Women of child-bearing potential should use effective contraception to prevent pregnancy and continue this until at least four weeks after cessation of apremilast treatment.264

Apremilast was detected in the milk of lactating mice at levels approximately 1.5-fold that of blood plasma samples.265,266 It is unknown whether apremilast or its metabolites are excreted in breastmilk in humans; therefore, apremilast should not be used while breastfeeding.264,266 No data are available regarding the influence of apremilast on fertility in humans.264

Ciclosporin. Ciclosporin crosses the placenta, but there is no evidence for teratogenicity.267 Experience with solid organ transplant recipients indicates that ciclosporin increases the chance of pregnancy-specific complications such as pre-eclampsia and low birthweight. In pregnant women with plaque psoriasis receiving ciclosporin, the advantages and disadvantages of continuing ciclosporin should be considered. Ciclosporin should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the foetus.267 The ethanol content of the Sandimmun Neoral formulations should also be taken into account in pregnant women.

If necessary, ciclosporin treatment can be continued with close follow-up, preferably together with an obstetrician.267,268
Ciclosporin is transferred into breastmilk; therefore, ciclosporin use is contraindicated during breastfeeding. There are limited data on the effect of ciclosporin on human fertility.

**Dimethyl fumarate**—Dimethyl fumarate is contraindicated in women of child-bearing potential who are not using appropriate contraception.\textsuperscript{269} Dimethyl fumarate should not be taken by women who are pregnant, breastfeeding or attempting conception. There are no published reports of patients becoming pregnant while on dimethyl fumarate.\textsuperscript{270} No data are available on the effects of dimethyl fumarate on female fertility.\textsuperscript{269} In patients with diarrhoea during treatment with dimethyl fumarate, the effect of oral contraceptives can be reduced. Additional use of barrier methods of contraception is therefore recommended.\textsuperscript{269}

It is unknown whether fumaric acid esters or metabolites are excreted in breastmilk; therefore, use of dimethyl fumarate is contraindicated during breastfeeding.\textsuperscript{269}

**Methotrexate**—Methotrexate is a folic acid antagonist known to be teratogenic in humans. In a recent review, statistically significantly higher proportions of microcephaly, craniosynostosis, tetralogy of Fallot, pulmonary valve atresia, limb reduction defects and syndactyly were found in newborns after maternal use of methotrexate in pregnancy.\textsuperscript{271} Spontaneous abortions were observed more frequently in pregnant women receiving methotrexate (less than 30 mg/week) compared to women with comparable diseases treated with other medications (42.5% vs. 22.5%).\textsuperscript{272}

Therefore, where relevant, women should be counselled about pregnancy and breastfeeding and should not conceive while taking methotrexate.\textsuperscript{272} Recent EMA guidelines recommend discontinuing methotrexate for 6 months before attempting conception, which is a change from the previous recommendations of 3 months.\textsuperscript{273} No evidence pertaining to the standard dose of methotrexate (5–30 mg/week) for inflammatory diseases is cited for this change of recommendation. The practice of the guideline group differs from this in favour of a shorter period of discontinuation (3 months).

It is recommended that sexually active women have a pregnancy test prior to starting therapy and use two methods of contraception throughout the period of methotrexate treatment. In the event of pregnancy during methotrexate therapy, immediate referral to an obstetrician is required.\textsuperscript{274} Methotrexate influences oogenesis and possibly can reduce fertility, especially in high doses. In most patients, this is reversible after stopping methotrexate.\textsuperscript{272} Methotrexate is excreted into breastmilk and so should not be used when breastfeeding.

**Recommendations (non-biologic systemic drugs)** When providing advice on use of systemic therapies in women planning conception or who are pregnant, prescribers are advised to use these recommendations with reference to the individual SmPC.

**Biologic drugs** Data from studies reporting pregnancy outcomes in women exposed to biologic treatments during conception and/or pregnancy were recently comprehensively reviewed as part of the British Association of Dermatologists guidelines for biologics use in psoriasis.\textsuperscript{275} All of the biologic agents that are currently licensed for psoriasis except certolizumab pegol contain a human IgG1 Fc region and are actively transported across the placenta via neonatal Fc receptors.\textsuperscript{276,277} Active placental transfer is thought to be very low during the first trimester when organogenesis takes place; hence, the theoretical risk of teratogenicity of biologics is low. Active transfer can, however, occur around 13 weeks’ gestation and increases significantly after 20 weeks’ gestation. This increasing exposure to biologics during the second and third trimesters is hypothesized to adversely affect fetal development, leading to potential risk of neonatal immunosuppression and greater risk of neonatal infections.\textsuperscript{278} Biologic therapies typically disappear from an infant’s serum within the first six months of life.

In contrast, certolizumab pegol is the only PEGylated humanized antigen-binding fragment of a TNF antagonist and it lacks a Fc domain.\textsuperscript{279} Certolizumab pegol therefore does not bind to the human neonatal Fc receptor and it is not actively transferred across the placenta. This was underscored by an analysis of 31 pregnancies exposed to infliximab, adalimumab and certolizumab pegol (for inflammatory bowel disease), in which the median levels of infliximab, adalimumab and certolizumab pegol in the cord blood of infants compared with that of mother were 160%, 153% and 3.9%, respectively.\textsuperscript{280} Infliximab and adalimumab could be detected in the infants for as long as 6 months. Postmarketing prospective pharmacokinetic research has confirmed no/minimal transfer of certolizumab pegol via the placenta (CRIB study, \(n = 16\))\textsuperscript{281} and into breastmilk (CRADLE study, \(n = 19\)).

Population-based cohort studies that report pregnancy outcomes in women exposed to biologics during conception and/or pregnancy are limited to TNF antagonist exposure only\textsuperscript{283–295} (see respective table). No evidence was identified on the use of IL-12/IL-23p40, IL-17 or IL-23p19 inhibitor biologics. Overall, the available studies identified no clear evidence of drug-specific harm to the fetus following TNF antagonist exposure with respect to congenital malformations, live births, preterm births or neonatal infections.\textsuperscript{283–295} One study (in inflammatory bowel disease) addressed maternal infection, indicating a potential increased risk to the mother following TNF antagonist exposure.\textsuperscript{287}

The evidence is overall limited since most studies involved small cohorts that may be underpowered to demonstrate small but significant risks associated with the treatments. Most of the evidence also relates to women with other chronic
inflammatory conditions such as inflammatory bowel disease or arthritis rather than psoriasis specifically. Several of the outcomes were poorly defined and heterogeneous, making it difficult to ascertain whether or not a pattern of specific birth defects was occurring. There is also a paucity of information on long-term outcomes for children born to women receiving biologics.

Recommenda

All biologic drugs currently licensed for psoriasis (with the exception of certolizumab pegol) are actively transferred to the fetus during the second and third trimester, and the impact of this on neonatal development and risk of infection (to both mother and baby) has not been adequately studied.

Necessity for continuing contraception immediately following biologic treatment cessation

There is no general consensus on how long contraception needs to be continued after stopping treatment with a biologic. Table 7 gives an overview of the recommended minimum time lag between stopping a biologic treatment and conception, as stated in the respective SmPCs. For treatments with a good safety profile during pregnancy, continuation of contraception immediately following treatment cessation may not be as relevant as for treatments with an unknown or less favourable safety profile. It is worth noting, that active placental transfer of biologics starts to occur around 13 weeks’ gestation and increases significantly after 20 weeks’ gestation. The specific half-lives of the respective drugs impact the remaining drug level at these time points.

Paternal use

In men who are planning conception, the effects of systemic medications on both fertility and fetal development are important considerations. However, there are very limited data on the impact of paternal exposure to systemic medications, particularly with respect to teratogenicity and longer-term sequelae.

Acitretin. Acitretin has no known effect on male fertility.296 Traces of acitretin have been reported in the semen of men; however, there is no evidence of teratogenicity at conception as the main at-risk period is 4–6 weeks later.297 Although ongoing exposure via direct contact with semen during unprotected sexual intercourse after conception is of low risk, the barrier method of contraception postconception may be considered.265

Apremilast. There are no available data for the impact of paternal exposure to apremilast on male fertility or pregnancy outcomes. In animal studies in mice, no adverse effects on fertility were observed in males at exposure levels threefold clinical exposure.8

Ciclosporin. There is no evidence that paternal use of ciclosporin affects male fertility; however, there is a paucity of studies on this.265,298,299 Recent systematic reviews of cohort study data showed no impact on pregnancy outcomes.265,298 This includes data from a Danish registry study of 247 children conceived during paternal use of ciclosporin, which found no association between paternal exposure to ciclosporin and increased risk of congenital abnormalities.300

Fumarates. A recent European consensus meeting concluded that contraception for males receiving fumarates is not required, although there is a paucity of evidence.269
Methotrexate. Fertility—A recent systematic review identified 48 male exposures to methotrexate, 298 of which there were two isolated case reports of oligospermia (one reversible and one irreversible).301,302 Another five publications comprising the remaining 46 exposures concluded that there was no impact of methotrexate on male fertility. 298 A case series of 26 men receiving methotrexate who had their semen examined using radioactive phosphorus for testicular histology and spermatogenic function showed no negative impact on fertility.303 Another study compared semen parameters from ten men treated with methotrexate for severe psoriasis with those of ten men using topical steroids and found that those taking methotrexate were significantly more likely to have normal semen parameters.304

Pregnancy outcomes—Paternal methotrexate use has not been shown to cause teratogenicity or adverse pregnancy outcomes. A recent systematic review which reported 1511 periconception paternal methotrexate exposures concluded that there was no link between paternal methotrexate exposure and adverse pregnancy outcomes or congenital malformations.299 The largest cohort studies, comprising national registry data300,305,306 and longer-term outcomes,307 showed no increased risk of paternal methotrexate exposure on pregnancy outcomes.

Although the above data do not support the need for any washout period for methotrexate, further evidence is required before this can be recommended. Recent EMA guidelines recommend discontinuing methotrexate for six months before attempting conception, which is a change from the previous recommendations of three months.273 No evidence pertaining to the standard dose of methotrexate (5–30 mg/week) for inflammatory diseases is cited for this change of recommendation. The practice of the guideline group differs from this in favour of a shorter period of discontinuation (3 months).

Biologics. Although there are limited available data, cohort studies of TNF antagonists found no evidence for impairment in fertility during paternal use.265,299 A systematic review highlighted that sperm motility and vitality may even improve under TNF antagonist therapy, possibly due to a decrease in disease activity.308 Cohort studies (total of 60 exposures with outcome events documented in 28 cases) involving a range of TNF antagonists (adalimumab, certolizumab pegol, etanercept, infliximab) also demonstrated no evidence for an association between impaired pregnancy outcomes and paternal use of TNF antagonist therapy at the time of conception.265,298,308

There are no studies which have assessed the potential impact of paternal exposure to other biologic agents including IL-12/IL-

---

**Table 7 Overview of minimum time between stop of treatment and conception as given by respective SmPC**

| Infliximab | Adalimumab | Etanercept | Ustekinumab | Secukinumab | Apremilast* |
|------------|------------|------------|-------------|-------------|-------------|
| 6 months313 | 5 months32 | 3 weeks    | 15 weeks88  | 20 weeks82  | No information provided in SmPC, 28 days advised by Celgene |
| Ixekizumab | Certolizumab | Brodalumab | Tildrakizumab | Gusekumab | Risankizumab |
| 10 weeks   | 5 months*  | 12 weeks   | 17 weeks    | 12 weeks    | 21 weeks    |

*Certolizumab is the suggested biologic treatment option, for women who are planning conception or are pregnant and require a systemic therapy, see also respective chapters.

---

1Due to personal-financial conflict of interest 3 abstentions

---

**EXPERT CONSENSUS**

| **We suggest** certolizumab pegol as a first line choice when starting biologic therapy in women planning conception (when a biologic is considered essential to use in pregnancy) and when it is necessary to start a systemic therapy during the second or third trimester. |
|------------|
| IRECTION |

| **We suggest** stopping biologic therapy in the second and third trimester (except certolizumab pegol) to minimise fetal exposure and limit potential infection risk to the neonate. |
|------------|
| irection |

| **We suggest against** using live or live attenuated vaccines in infants (up to 6 months of age) whose mothers received biologic therapy beyond 16 weeks gestation, unless the benefit of the vaccination clearly outweighs the theoretical risk of administration. |
|------------|
| irection |

| **We recommend** consultation and information sharing across specialties, including with an obstetrician with expertise in caring for pregnant women with medical problems. |
|------------|
| irection |

| **We recommend** the collection of maternal exposure to medications and pregnancy outcome data in national safety registries where available. |
|------------|
| irection |
In psoriasis patients, vaccination using dead A narrative literature review was conducted in November 2019.

3.13 Vaccinations: How should vaccinations in psoriasis patients on systemic treatment be managed?

A narrative literature review was conducted. 

Results/Answer In psoriasis patients, vaccination using dead vaccines and live vaccines can be performed at any time, unless systemic treatment is given that necessitates a different strategy. Psoriasis on its own should not be considered a reason to deviate from standard vaccination recommendations.

Before initiating a systemic treatment, vaccination status should be checked and completed if possible. Annual flu vaccination and vaccination against pneumococci (age > 60) is particularly recommended. National recommendations for vaccination should be followed.309

When psoriasis patients receive any kind of systemic therapy dead vaccines can be given, however, vaccination responses may be decreased.

Therefore, it is recommended to use inactivated vaccines 2 weeks and attenuated live zoster vaccine 2–4 weeks prior to initiation of systemic therapy. If patients receiving systemic/immunosuppressive therapy, inactivated vaccines should be given without treatment interruption.310

Live vaccines (including measles–mumps–rubella, varicella) can be used in patients receiving acitretin, apremilast and fumarates. Live vaccines are contraindicated in psoriasis patients treated with ciclosporin and methotrexate, the tumour necrosis factor alpha (TNFa)-antagonists adalimumab, certolizumab, etanercept and infliximab, and the interleukin 17A-antibodies ixekizumab and secukinumab, and the interleukin 17RA-antibody brodalumab.

Generally, administration of a live vaccine after discontinuation of immunosuppressive therapy should be determined considering factors including its half-life (i.e. 5 half-lives) or mechanism of action. For the following medications, the respective SmPC provides recommendations with regard to timing is available:

Guselkumab: Wait two weeks after live vaccine, start vaccination 12 weeks after last dose.311

Risankizumab: Wait 4 weeks after live vaccine, start vaccination 21 weeks after last dose.312

Ustekinumab: Wait two weeks after live vaccine, start vaccination 15 weeks after last dose.313

Tildrakizumab: Wait four weeks after live vaccine, start vaccination 17 weeks after last dose.314

For live or live-attenuated vaccines in infants (up to 6 months of age) whose mothers received biologic therapy beyond 16 weeks’ gestation, see chapter pregnancy.

3.14 Immunogenicity of targeted therapies in psoriasis

Narrative review of the existing literature was conducted.

Results/Answer A lack of fully comparable information on the formation of antidrug antibodies against targeted therapies in psoriasis has been identified in the course of the guideline’s development. Within the scope of this version of the guideline, a thorough systematic search of the available evidence has not been feasible and a consensus on consequent measures has not been achieved. The author group acknowledges that there is evidence of a beneficial effect of the combination of methotrexate with adalimumab from psoriasis patients and MTX with infliximab in rheumatoid arthritis or Crohn’s disease patients to reduce the formation in ADA.

The guideline group encourages researches to pursue further investigations into the field of antidrug antibodies and to generate data that allows comparison between different drugs and that can lead clinically relevant recommendations.

The authors encourage further opinion papers, narrative or preferably systematic reviews to further advance the discussion on immunogenicity.315–318

3.15 COVID-19: Guidance for systemic therapy of psoriasis during COVID-19 pandemic

The most up-to-date version of this chapter can be found alongside the main guideline document on the EDF website.

References

1 Guyatt G, Oxman AD, Akl EA et al. GRADE guidelines: 1. Introduction–GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383–394.
2 Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidem 2011; 64: 380–382.
3 The GRADE Working Group, In, Vol. 2018. 2018.
4 Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 1: Diagnosis. J Eur Acad Dermatol Venereol 2017; 31: 9–19.
5 Werner RN, Nikkels AF, Marinovic B et al. European consensus-based (S2k) Guideline on the Management of Herpes Zoster - guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: Treatment. J Eur Acad Dermatol Venereol 2017; 31: 20–29.
6 Shbdian E, Chaimani A, Afach S et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev 2020; 1: Cd011355.
7 Nast A, Gisondi P, Ormerod AD et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris – Update 2015 – Short version – EDF in cooperation with EADV and ICP. J Eur Acad Dermatol Venereol 2015; 29: 2277–2294.
8 Nast A, Spuls PI, van der Kraai G et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - Update Apremilast and Secukinumab - EDF in cooperation with EADV and ICP. J Eur Acad Dermatol Venereol 2017; 31: 1951–1963.
9 Elmamoun M, Chandran V. Role of methotrexate in the management of psoriatic arthritis. Drugs 2018; 78: 611–619.
10 Mclnnes IB, Nash P, Ritchlin C et al. Secukinumab for psoriatic arthritic: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis. J Comp Eff Res 2018; 7: 1107–1123.
11 Mease PJ, Smolen JS, Behrens F et al. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79: 123–131.
12 Nash P, Mclnnes IB, Mease PJ et al. Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison. Rheumatol Ther 2018; 5: 99–122.
13 Dressler C, Eiser L, Pham PA, Nast A. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol 2019; 33: 1249–1260.
14 Murashima A, Watanabe N, Ozawa N, Saito H, Yamaguchi K. Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant’s serum. Ann Rheum Dis 2009; 68: 1793–1794.
15 Gossec L, Smolen JS, Gaujoux-Viala C et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71: 4–12.
16 Nast A, Amelunxen L, Augustin M et al. S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 2 - Special patient populations and treatment situations. J Dtsch Dermatol Ges 2018; 16: 806–813.
17 Amatore F, Villani AP, Tauber M, Viguier M, Guillot B. French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol 2019; 33: 464–483.
18 Elmete CA, Leonardi CL, Davis DMK et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 2019; 80: 1073–1113.
19 Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 2010; 162: 633–636.
20 Augustin M, Reich K, Glaeske G, Schafer I, Radtke M. Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany. Acta Dermato-Venereol 2010; 90: 147–151.
21 Targan SR, Feagan B, Vermeire S et al. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease. Am J Gastroenterol 2016; 111: 1599–1607.
22 Hueter W, Sands BE, Lewitzky S et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 2012; 61: 1693–1700.
23 Armstrong A, Paul C, Puig L et al. Safety of Ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther 2019; 10(1): 133–150.
24 Deodhar A, Mease PJ, Mclnnes IB et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, pustular arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther 2019; 21: 111.
25 Feagan BG, Sandborn WJ, D’Haens G et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 2017; 389: 1699–1709.
26 Reich K, Armstrong AW, Langley RG et al. Guselkumum versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394: 831–839.
27 Whitlock SM, Enos CW, Armstrong AW et al. Management of psoriasis in patients with inflammatory bowel disease. From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018; 78: 383–394.
28 Feagan BG, Panes J, Ferrante M et al. Risankizumab in patients with moderate to severe Crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol 2018; 3: 671–680.
29 Visvanathan S, Baum P, Salas A et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active Crohn’s disease: results from a randomised phase II biopsy sub-study. J Crohns Colitis 2018; 12: 1170–1179.
30 Grossberg LB. A case report of successful treatment of Crohn’s disease and psoriasis with guselkumab. Inflamm Bowel Dis 2019; 25: 684.
31 Berman HS, Villa NM, Shi VY, Hsiao JL. Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn’s Disease. J Dermatol Treat 2019; 1–3.
32 Danese S, Neurath M, Kopon A et al. OP006 Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study. J Crohns Colitis 2018; 12: S004–S005.
33 Patel V, Wang Y, MacDonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2014; 2014: Cd006884.
34 McDonald JW, Wang Y, Tsoulis DJ, MacDonald JK, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2014; 2014: Cd003459.
35 Chande N, Wang Y, MacDonald JK, McDonald JW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2014; 2014: Cd006618.
36 Herfarth H, Barnes EL, Valentine JF et al. Methotrexate is not superior to placebo in maintaining steroid-free response or remission in ulcerative colitis. Gastroenterology 2018; 155(1098–108): e9.
37 Melo FJ, Magina S. Clinical management of Anti-TNF-alpha-induced psoriasis or psoriasiform lesions in inflammatory bowel disease patients: a systematic review. Int J Dermatol 2018; 57: 1521–1532.
38 Laharie D, Bourreille A, Branche J et al. Long-term outcome of patients with steroid-refractory acute severe UC treated with cyclosporin or infliximab. Gut 2018; 67: 237–243.
39 Dhana A, Yen H, Yen H, Cho E. All-cause and cause-specific mortality in psoriasis: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 80: 1332–1343.
40 Vaengebjerg S, Skov L, Egeberg A. Prevalence LND. Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol 2020; 156: 421.
41 Peleva E, Exton LS, Kelley K, Kleyen CE, Mason KJ, Smith CH. Risk of cancer in patients with psoriasis on biological therapies: a systematic review. Br J Dermatol 2018; 178: 103–113.
42 Garcia-Doval I, Hernandez MV, Vanaclocha F, Sellas A, de la Cuba P, Montero D. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts. Br J Dermatol 2017; 176: 643–649.
43 Holroyd CR, Seth R, Bukhari M et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 2019; 58: e3–e42.
44 Luo X, Deng C, Fei Y et al. Malignancy development risk in psoriatic arthritis patients undergoing treatment: A systematic review and meta-analysis. Semin Arthritis Rheum 2019; 48: 626–631.
45 Kim SC, Schneeweis S, Liu J et al. Biologic Disease-modifying antirheumatic drugs and risk of high-grade cervical dysplasia and cervical cancer in rheumatoid arthritis: a cohort study. Arthritis Rheumatol (Hoboken, N.J.) 2016; 68: 2106–2113.
46 Mercer LK, Low AS, Galloway JB et al. Anti-TNF therapy in women with rheumatoid arthritis with a history of carcinoma in situ of the cervix. Ann Rheum Dis 2013; 72: 143–144.
47 Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol 2019; 53: e1–e11.
48 Scott FI, Mamanti R, Brensinger CM et al. Risk of nonmelanoma skin cancer associated with the use of immunosuppressant and biologic agents in patients with a history of autoimmune disease and nonmelanoma skin cancer. JAMA Dermatol 2016; 152: 164–172.
49 Shelby E, Laharie D, Scott FI et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology 2016; 151: 97–109.e4.
50 Cohen BE, Martires KJ, Ho RS. Psoriasis and the risk of depression in the US population: national health and nutrition examination survey 2009–2012. JAMA Dermatol 2016; 152: 73–79.
51 Egeberg A, Tyssen JP, Wu JJ, Skov L. Risk of first-time and recurrent depression in patients with psoriasis: a population-based cohort study. Br J Dermatol 2019; 180: 116–121.
52 Fleming P, Routhille C, Richer V et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol 2015; 29: 1063–1070.
53 Trubo MJ, Turroja M, Castano-Vinyllos G et al. Patients with moderate to severe psoriasis associate with higher risk of depression and anxiety symptoms: results of a multivariate study of 300 Spanish individuals with psoriasis. Acta Dermato-Venereol 2019; 99: 417–422.
54 Abbott R, Whear R, Nikolou V et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. J Psychosom Res 2015; 79: 173–184.
55 Carrascosa JM, Rebollo F, Gomez S, De-la-Cueva P. Effects of etanercept on the patient-perceived results (PROs) in patients with moderate-to-severe plaque psoriasis: systematic review of the literature and meta-analysis. J Dermat Treat 2018; 29: 806–811.
56 Gordon KB, Armstrong AW, Han C et al. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol 2018; 32: 1940–1949.
57 Griffiths CE, Fava M, Miller AH et al. Impact of Ixekizumab treatment on depressive symptoms and systemic inflammation in patients with moderate-to-severe psoriasis: an integrated analysis of three phase 3 clinical studies. Psychother Psychosom 2017; 86: 260–267.
58 Schneider A, Poppe M, Hametner C et al. Impact of fumaric acid esters on cardiovascular risk factors and depression in psoriasis: a prospective pilot study. Arch Dermatol Res 2015; 307: 413–424.
59 Kim SJ, Park MY, Pak K et al. Improvement of depressive symptoms in patients with moderate-to-severe psoriasis treated with ustekinumab: an open label trial validated using beck depression inventory, Hamilton depression rating scale measures and (18)fluorodeoxyglucose (FDG) positron emission tomography (PET). J Dermatol Treat 2018; 29: 761–768.
60 Strober B, Gooderham M, de Jong E et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Am Acad Dermatol 2018; 78: 70–80.
61 Arican O, Sasmaz S, Ozbulut O. Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venereol 2006; 20: 464–465.
62 Henderson CA, Highton AS. Depression induced by etretinate. BMJ 1989; 298: 964.
63 Hayes J, Koo J. Depression and acitretin: a true association or a class labeling? J Drugs Dermatol 2011; 10: 409–412.
64 Starling J, 3rd, Koo J. Evidence based or theoretical concern? Pseudotumor cerebri and depression as acitretin side effects. J Drugs Dermatol 2005; 4: 690–696.
65 European Medicines Agency. Retinoid-containing medicinal products. In. 2018.
66 European Medicines Agency. Acitretin SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 22 Oct 2019.
67 Lebwohl M, Strober B, Menter A et al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med 2015; 373: 1318–1328.
68 Papp KA, Reich K, Paul C et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2016; 175: 273–286.
69 Beck KM, Koo J. Brodalumab for the treatment of plaque psoriasis: up-to-date. Expert Opin Biol Ther 2019; 19: 287–292.
70 European Medicines Agency. Kyntheum SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 25 sep 2017.
71 Crowley J, Thaci D, Joly P et al. Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for >=156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). J Am Acad Dermatol 2017; 77(10–7): e1.
72 Kavanaugh A, Gladman DD, Edwards C et al. Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis. Arthritis Res Ther 2019; 21: 118.
73 European Medicines Agency. Otezla (apremilast): New important advice regarding suicidal ideation and behaviour. In: Celgene Europe Limited. 2016.
74 European Medicines Agency. Otezla SmPC and Patient Leaflet. In: The electronic medicines compendium. Last updated 10 Sep 2019.
75 Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatol 2013; 149: 84–91.
76 Mamizadeh M, Tardeh Z, Azami M. The association between psoriasis and diabetes mellitus: A systematic review and meta-analysis. Diabetes Metab Syndr 2019; 13: 1405–1412.
77 Coto-Segura P, Eiríis-Salvado N, Gonzalez-Lara L et al. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Dermatol 2013; 169: 783–793.
78 Lee MS, Lin YR, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol 2014; 70: 691–698.
79 Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014; 130: 837–844.
80 Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes 2012; 2: e54.
81 Dehpouri T, Rokni GR, Narenjbon NA et al. Evaluation of the glycemic effect of methotrexate in psoriatic arthritis patients with metabolic syndrome: A pilot study. Dermatol Rep 2019; 11: 7965.
82 Owczarczyk-Sazonek A, Drozdowski M, Maciejewska-Radomska A, Choszcz D, Placek W. The effect of subcutaneous methotrexate on markers of metabolic syndrome in psoriatic patients - preliminary report. Postepy Dermatol Alergol 2018; 35: 53–59.
83 Wu JJ, Liu L, Asgari MM et al. Initiation of TNF inhibitor therapy and change in physiologic measures in psoriasis. J Am Acad Dermatol 2014; 28: 1380–1387.
84 Rosenberg P, Urvitz H, Johannesson A et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment. J Hepatol 2007; 46: 1111–1118.
85 Singh JA, Guyatt G, Ogdie A et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Care Res 2019; 71: 2–29.
86 Gisondi P, Cazzaniga S, Chimenti S et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian PsoCare Registry. J Am Acad Dermatol 2015; 27: 30–41.
87 Cotovio P, Neves M, Rodrigues L et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. Transplant Proc 2013; 45: 1079–1083.
88 Sato T, Inagaki A, Uchida K et al. Diabetes mellitus after transplant: relationship to pretransplant glucose metabolism and tacrolimus or cyclosporine A-based therapy. Transplantation 2003; 76: 1320–1326.
89 Pestreta S, Diamentino F, Veloso L, Fidalgo A, Ferreira A. Effects of etanercept treatment on lipid profile in patients with moderate-to-severe chronic plaque psoriasis: a retrospective cohort study. Eur J Dermatol 2011; 21: 916–920.
90 Gisondi P, Cotena C, Tessari G, Girolomoni G. Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. Br J Dermatol 2013; 168: 1124–1127.
91 Kausik SB, Lebowohl MG. Psoriasis: Which therapy for which patient? Psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol 2019; 80: 27–40.
92 da Silva BS, Bonfa E, de Moraes JC et al. Effects of anti-TNF therapy on glucose metabolism in patients with anklylosing spondylitis, psoriatic arthritis or juvenile idiopathic arthritis. Biologics 2010; 38: 567–569.
93 Costa L, Caso F, Atteno M et al. Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol 2014; 33: 833–839.
94 Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res 2007; 299: 461–465.
95 Kofoid K, Clemmensen A, Mikkelsen UR, Simonsen L, Andersen O, Ngiadecki R. Effects of anti-tumor necrosis factor therapy on body composition and insulin sensitivity in patients with psoriasis. Arch Dermatol 2012; 148: 1089–1091.
96 Campanati A, Ganzetti G, Di Sario A et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839–846.
97 Marra M, Campanati A, Testa R et al. Effect of etanercept on insulin sensitivity in nine patients with psoriasis. Int J Immunopathol Pharmacol 2007; 20: 731–736.
of oxidative stress mediated activation of NF-kappaB signaling pathways. Pharmacol Rep 2018; 70: 993–1000.

135 Peters M, Liu S, Wulf P, et al. Lack of effect of TNF alpha blockade therapy on circulating adiponectin levels in patients with autoimmune disease: results from two independent prospective studies. Ann Rheum Dis 2010; 69: 1687–1690.

136 Strober B, Bell J, Yanam A, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. Br J Dermatol 2008; 159: 322–330.

137 Gisondi P, Lora V, Bonaugur C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol 2013; 168: 749–755.

138 Eder L, Joshi AA, Dey AK, et al. Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic arthritis. Arthritis Rheumatol (Hoboken, N.J.) 2018; 70: 408–416.

139 Gelfand JM, Shin DB, Alavi A, et al. A phase IV, randomized, double-blind, placebo-controlled crossover study of the effects of ustekinumab on vascular inflammation in psoriasis (the VIP-U trial). J Invest Dermatol 2020; 140: 85–93.e2.

140 Bilborough W, Keen H, Taylor A, O’Driscoll GL, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006; 26: 1125–1131.

141 Tam LS, Li EK, Shang Q, et al. Tumour necrosis factor alpha blockade is associated with sustained regression of carotid intima-media thickness for patients with active psoriatic arthritis: a 2-year pilot study. Ann Rheum Dis 2011; 70: 705–706.

142 Pina T, Corrales A, Lopez-Mejias R, et al. Anti-tumour necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol 2016; 43: 1267–1272.

143 von Stubel E, Reich K, Thaci D, et al. Impact of secukinumab on endothelial dysfunction and other cardiovascular disease parameters in psoriasis patients over 52 weeks. J Investig Dermatol 2019; 139: 1054–1062.

144 Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapy on the incidence of myocardial infarction: a cohort study. Br J Dermatol 2011; 165: 1066–1073.

145 Leisner MZ, Lindorff R, Gniadecki R, et al. Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. J Eur Acad Dermatol Venereol 2018; 32: 2185–2190.

146 Rya C, Leopardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864–871.

147 Wu JJ, Poon K-Y, Channual JC, Shen AY-J. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol 2012; 148: 1244–1250.

148 Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. J Intern Med 2013; 273: 197–204.

149 Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P. Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate. J Am Acad Dermatol 2017; 76: 81–90.

150 Reich K, Langley RG, Lebowoth M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862–872.

151 Papp KA, Griffiths CE, Gordon K, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol 2013; 168: 844–854.
Ponikowski P, Voors AA, Anker SD, et al. Impact of biological therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol 2017; 176: 890–901.

Champs B, Degboe Y, Barretche T, Cantagrel A, Ruyssen-Witrand A, Constantin A. Short-term risk of major adverse cardiovascular events or congestive heart failure in patients with psoriatic arthritis or psoriasis initiating a biological therapy: a meta-analysis of randomised controlled trials. RMD Open 2019; 5: e000763.

Rungapirromnan W, Yiu ZZN, Warren RB, Griffiths CEM, Ashcroft Database Syst Rev 2014; 707.

Lee MP, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis. JAMA Dermatol 2019; 155: 700–707.

Pokownikowski P, Voors AA, Anker SD et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Rev Espanola Cardiol (English ed.) 2016; 69: 1167.

Yokoyama T, Vaca L, Rossen RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-alpha in the adult mammalian heart. J Clin Invest 1993; 92: 2303–2312.

Torre-Amione G, Bozkurt B, Deswal A, Mann DL. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol 1999; 14: 206–210.

Deswal A, Bozkurt B, Seta Y et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224–3226.

Coletta AP, Clark AL, Banarjee P, Cleland JG. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur J Heart Fail 2002; 4: 559–561.

Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti TNFACTHER. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133–3140.

Singh JA, Wells GA, Christensen R et al. Association between cyclosporin neurotoxicity and hypomagnesemia. Lancet 2006; 368: 1658–1659.

Ermis U, Weis J, Schulz JB. PML in a patient treated with fumaric acid. Arch Dermatol Res 2013; 305: 313–326.

Ellis GN, Fradin MS, Messana JM et al. Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial. N Engl J Med 1991; 324: 277–284.

Tan TC, Robinson PJ. Mechanisms of calcineurin inhibitor-induced neurotoxicity. Transpl Rev 2006; 20: 49–60.

Arnold R, Pussell BA, Pianta TJ, Lin CS, Kiernan MC, Krishnan AV. Association between calcineurin inhibitor treatment and peripheral nerve dysfunction in renal transplant recipients. Am J Transplant 2013; 13: 2426–2432.

Thompson CB, Sullivan KM, June CH, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesemia. Lancet 1984; 2: 1116–1120.

Venci JV, Gandhi MA. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Ann Pharmacother 2013; 47: 1697–1702.

van Oosten BW, Killestein J, Barkhof F, Polman CH, Waatts MP. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med 2013; 368: 1658–1659.

Ermis U, Weiss J, Schulz JB. PML in a patient treated with fumaric acid. N Engl J Med 2013; 368: 1657–1658.

Stoppe M, Thoma E, Liebert UG et al. Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis. J Neurol 2014; 261: 1021–1024.

Sweetser MT, Dawson KT, Bozic C. Manufacturer’s response to case reports of PML. N Engl J Med 2013; 368: 1659–1661.

Buttmann M, Stoll G. Case reports of PML in patients treated for psoriasis. N Engl J Med 2013; 369: 1081.
Control and Prevention Clinical Practice Guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis 2017; 64: 111–115.

234 Desai N, Raste Y, Cooke NT, Harland CC. Quantiferon-TB Gold testing for tuberculosis in psoriasis patients commencing anti-tumour necrosis factor alpha therapy. Br J Dermatol 2008; 158: 1137–1138.

235 Ehlers S. Tumor necrosis factor and its blockade in granulomatous disease. J Eur Acad Dermatol Venereol 2018: 32(suppl 2): S10–S20.

236 World Health Organization. WHO Guidelines Approved by the Guidelines Review Committee. In: Tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization (c) World Health Organization 2018. 2018.

237 Golden MP, Vikram HR. Extrapulmonary tuberculosis: an overview. Am Fam Phys 2005; 72: 1761–1768.

238 Christensen WI. Genitourinary tuberculosis: review of 102 cases. Medicine 1974; 53: 377–390.

239 Simon HB, Weinstein AJ, Pasternak MS, Swartz MN, Kunz LJ. Genitourinary tuberculosis: review of 102 cases. J Infect Dis 1974; 129: 410–420.

240 National Collaborating Centre for Chronic Conditions, Centre for Clinical Practice. Tuberculosis Guideline for Tuberculosis Diagnosis and Management of Tuberculosis, and Measures for Its Prevention and Control. London: National Institute for Health and Clinical Excellence (UK) Royal College of Physicians of London. Updated text, Copyright (c) 2011, National Institute for Health and Clinical Excellence. 2011.

241 Schaberg T, Bauer T, Brinkmann F et al. Tuberculosis Guideline for Adults - Guideline for Diagnosis and Treatment of Tuberculosis including LTBI Testing and Treatment of the German Central Committee (DZK) and the German Respiratory Society (DGPI). Pneumologie (Stuttgart, Germany) 2017; 71: 325–397.

242 Doherty SD, Van Voorhees A, Lebwohl MG. Psoriasis: Which therapy for which patient: Focus on special populations and chronic infections. Br J Dermatol 2016; 175: 464–472.

243 Arias-Guillen M, Sanchez Menendez MM, Alperi M et al. High rates of tuberculosis skin test positivity due to methotrexate therapy: False positive results? Semin Arthritis Rheum 2018; 48: 538–546.

244 Cantini F, Nannini C, Niccoli L, Petrone L, Ippolito G, Goletti D. Risk of tuberculosis reactivation in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis receiving non-anti-TNF-targeted biologics. Mediators Inflamm 2017; 2017: 8909834.

245 Snait I, Bercovici E, Solomon-Cohen E et al. Active tuberculosis in patients with psoriasis receiving biologic therapy: a systematic review. Am J Clin Dermatol 2019; 20: 483–491.

246 Kaushik SB, Lebwohl MG, Psoriasis: Which therapy for which patient? Focus on special populations and chronic infections. Am Acad Dermatol 2019; 80: 43–53.

247 Epstein DJ, Dunn J, DeresaRK. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5: ofy174.

248 Fox RJ, Kita M, Cohen SL et al. BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety. Curr Med Res Opin 2014; 30: 251–262.

249 Cantini F, Niccoli L, Capone A, Petrone L, Goletti D. Risk of tuberculosis reactivation associated with traditional disease modifying anti-rheumatic drugs and non-anti-tumor necrosis factor biologics in patients with rheumatic disorders and suggestion for clinical practice. Expert Opin Drug Saf 2019; 18: 415–425.

250 Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676–1684.

251 Baddley JW, Cantini F, Goletti D et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective. Infect Dis Clin Pract 2018; 24(Suppl 2): S10–S20.

252 Cantini F, Niccoli J, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014; 91: 47–55.

253 Winthrop KL, Mariette X, Silva JT et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect 2018; 24(Suppl 2): S21–S40.

254 Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol 2019; 33: 1676–1684.

255 Lebwohl MG, Papp KA, Marangell LB et al. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. J Am Acad Dermatol 2018; 78: 81–89.e5.

256 Gordon KB, Strober B, Lebwohl M et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltiMMa-1 and UltiMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 2018; 392: 650–661.

257 Boyd AS, Morris LF, Phillips CM, Menter MA. Psoriasis and pregnancy: hormone and immune system interaction. Int J Dermatol 1996; 35: 169–172.

258 Murase JE, Chan KK, Garite TJ, Cooper DM, Weinstein GD. Hormonal effect on psoriasis in pregnancy and post partum. Arch Dermatol 2005; 141: 601–606.

259 Bobotis R, Gulliver WP, Monaghan K, Lynde C, Fleming P. Psoriasis and adverse pregnancy outcomes: a systematic review of observational studies. Br J Dermatol 2016; 175: 464–472.

260 Yang Y-W, Chen C-S, Chen Y-H, Lin H-C. Psoriasis and pregnancy: a nationwide population-based study. J Am Acad Dermatol 2011; 64: 71–77.

261 Lima XT, Janakiraman V, Hughes MD, Kimball AB. The impact of psoriasis on pregnancy outcomes. J Invest Dermatol 2012; 132: 83–91.

262 Bandoli G, Johnson DL, Jones KL et al. Potentially modifiable risk factors for adverse pregnancy outcomes in women with psoriasis. Br J Dermatol 2010; 163: 334–339.

263 European Medicines Agency. Acritretin 25mg Capsules - Summary of Product Characteristics (SmPC) - (emc). In.

264 European Medicines Agency. Otezla 30mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). In.

265 Rademaker M, Agnew K, Andrews M et al. Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis Collaboration. Australas J Dermatol 2018; 59: 86–100.

266 Gerosa M, ArgolimI, Artusi C, Chighizola CB. The use of biologics and small molecules in pregnant patients with rheumatic diseases. Expert Rev Clin Pharmacol 2018; 11: 987–998.

267 European Medicines Agency. Neonatal Soft Gelatin Capsules - Summary of Product Characteristics (SmPC) - (emc). In.

268 van der Kraaij GE, Balak DMW, Busard CI et al. Highlights of the updated Dutch evidence– consensus-based guideline on psoriasis 2017. Br J Dermatol 2019; 180: 31–42.

269 European Medicines Agency. Skilarence 30mg Gastro-resistant Tablets - Summary of Product Characteristics (SmPC) - (emc). In.

270 Mrowietz U, Barker J, Boehncke WH et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. J Eur Acad Dermatol Venereol 2018; 32(Suppl 3): 3–14.

271 Verberne EA, de Haan E, van Tintelen JP, Lindhout D, van Haelst MM. Fetal methotrexate syndrome: A systematic review of case reports. Reprod Toxicol 2019; 87: 125–139.
272 European Medicines Agency. Methotrexate 2.5mg Tablets - Summary of Product Characteristics (SmPC) - (emc). In.
273 European Medicines Agency. Nordimet - EPAR. 2016.
274 Warren RB, Weatherhead SC, Smith CH et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol 2016; 175: 23–44.
275 Smith CH, Jabbar-Lopez ZK, Yiu ZZ et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol 2017; 177: 626–636.
276 Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol 2009; 104: 228–233.
277 Malek A, Sager R, Kuhn P, Nicolaides KH, Schneider H. Evolution of materno-fetal transport of immunoglobulins during human pregnancy. Am J Reprod Immunol 1996; 36: 248–255.
278 Pottinger E, Woolf RT, Exton LS, Burden AD, Nelson-Piercy C, Smith CH. Exposure to biological therapies during conception and pregnancy: a systematic review. Br J Dermatol 2018; 178: 95–102.
279 Ferrante M, Vermeire S, Rutgeerts P. Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf 2014; 13: 255–266.
280 Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 286–292. quiz e24.
281 Mariette X, Förger F, Abraham B et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Ann Rheum Dis 2018; 77: 228–233.
282 Cloos M, Tizard R, Hwang C et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis 2017; 76: 1890–1896.
283 Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoeconomic Drug Saf 2017; 26: 1109–1118.
284 Burmester GR, Landewé R, Genovese MC et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76: 414–417.
285 Bröms G, Granath F, Stephansson O, Kieler H. Preterm birth in women with inflammatory bowel disease – the association with disease activity and drug treatment. Scand J Gastroenterol 2016; 51: 1462–1469.
286 Bröms G, Granath F, Ekborn A et al. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol 2016; 14: 234–241.e1–5.
287 Luu M, Benzine M, Doret M et al. Continuous anti-TNFα use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National health insurance database (EVAISON). Am J Gastroenterol 2018; 113: 1669–1677.
288 Casanova MJ, Chaparro M, Doménech E et al. Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013; 108: 433–440.
289 Cooper WO, Cheetham TC, Li D-K et al. Brief report: Risk of adverse fetal outcomes associated with immunosuppressive medications for chronic immune-mediated diseases in pregnancy. Arthritis Rheumatol (Hoboken, N.J.) 2014; 66: 444–450.
290 Weber-Schoendörfer C, Oppermann M, Wacker E et al. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015; 80: 727–739.
291 Díaz-Citrin O, Ochoterenaski-Valodarsky A, Shechtman S, Ornay A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol 2014; 43: 78–84.
292 Schnitzler F, Fidder H, Ferrante M et al. Outcome of pregnancy in women with inflammatory bowel disease treated with anti-tumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846–1854.
293 Seirafl M, de Vroeby B, Amiot A et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther 2014; 40: 363–373.
294 Verstappen SMM, King Y, Watson KD, Symmons DPM, Hyrich KL. Br Br rheumatoid control society group BSRB. Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2011; 70: 823–826.
295 Cloos MEB, Scheuerle AE, Chambers C et al. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database. Arthritis Rheumatol (Hoboken, N.J.) 2018; 70: 1399–1407.
296 Porsch EM, Ruzicka T, Przybilla B, Schill WB. Andrological investigations in men treated with acitretin (Ro 10–1670). Andrologia 1999; 31: 479–482.
297 Geiger JN, Walker M. Is there a reproductive safety risk in male patients treated with acitretin (neotigason/soriatane? Dermatology (Basel) 2002; 205: 105–107.
298 Mouyis M, Flint JD, Giles IP. Safety of anti-rheumatic drugs in men trying to conceive: A systematic review and analysis of published evidence. Semin Arthritis Rheum 2019; 48: 911–920.
299 Semet M, Paci M, Saia-Magnan J et al. The impact of drugs on male fertility: a review. Andrology 2017; 5: 640–663.
300 Egeberg A, Gislason GH, Nast A. Birth outcomes in children fathered by men treated with immunosuppressant drugs before conception: a Danish population-based cohort study. J Invest Dermatol 2017; 137: 1790–1792.
301 Pandhi D, Gupta R, Singal A. Gynecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol 2006; 31: 138–140.
302 Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 215–217.
303 El-Beheiry A, El-Mansy E, Kamel N, Salama N. Methotrexate and fertility in men. Arch Androl 1979; 3: 177–179.
304 Grunnet E, Nyfors A, Hansen KB. Studies of human semen in topical corticosteroid-treated and in methotrexate-treated psoriatics. Dermatolological 1977; 154: 78–84.
305 Eck LK, Jensen TB, Mastrogiannis D et al. Risk of adverse pregnancy outcome after paternal exposure to methotrexate within 90 days before pregnancy. Obstet Gynecol 2017; 129: 707–714.
306 Winter RW, Larsen MD, Magnussen B, Friedman S, Kammerlander H, Nørgård BM. Birth outcomes after preconception paternal exposure to methotrexate: A nationwide cohort study. Reprod Toxicol 2017; 74: 219–225.
307 Friedman S, Larsen MD, Magnussen B, Jørgensen LR, de Silva P, Nørgård BM. Paternal use of azathioprine/6-mercaptopurine or methotrexate within 3 months before conception and long-term health outcomes in the offspring: A nationwide cohort study. Reprod Toxicol 2017; 73: 196–200.
308 Puchner R, Danninger K, Puchner A, Pieringer H. Impact of TNF-blocking agents on male sperm characteristics and pregnancy outcomes in fathers exposed to TNF-blocking agents at time of conception. Clin Exp Rheumatol 2012; 30: 765–767.
309 Wagner N, Assmus F, Arendt G et al. Impfen bei Immundefizienz : Anwendungshinweise zu den von der Ständigen Impfkommission empfohlenen Impfungen. (IV.) Impfen bei Autoimmunkrankheiten, bei anderen chronisch-entzündlichen Erkrankungen und unter immunmodulatorischer Therapie. Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz 2019; 62: 494–515.
310 Papp KA, Harauz V, Kumar D et al. Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutaneous Med Surg 2019; 23: 50–74.
311 European Medicines Agency. Tremfya [Tremfya: EPAR - Product Information]. In. 2017.

312 European Medicines Agency. Skyrizi - EMEA/H/C/004759 - IA/0006. In. 2019.

313 European Medicines Agency. Stelara [INN-Ustekinumab: EPAR - Product Information]. In. 2009.

314 European Medicines Agency. IlumetriTM (Tildrakizumab) Summary of product characteristics. In. 2019.

315 Goss SL, Klein CE, Jin Z et al. Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO trial. *Clin Ther* 2018; 40: 309–319.

316 Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D’Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; 45: 1128–1134.

317 Van der Kraaij GE. EADV Congress Poster, FC02.06.

318 Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K. Immunogenicity of biologic therapies in psoriasis Myths, facts and a suggested approach. *J Eur Acad Dermatol Venereol* 2021; 35: 329–337.